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Abstract 
This thesis explored the effects of cholesterol and SP-A on surfactant function in vitro, and 
lung function in vivo. In the first experiment, we determined whether SP-A could mitigate 
cholesterol-mediated surfactant dysfunction. We hypothesized that SP-A can mitigate the 
surfactant inhibition caused by high cholesterol.  In the second experiment, we tested the 
contribution of diet-induced serum hypercholesterolemia to surfactant composition and the 
development of lung injury in rats.  We hypothesized that serum hypercholesterolemia would 
increase the amount of cholesterol in surfactant and would cause rats to develop more severe 
lung injury.  Our results indicate that SP-A mitigates cholesterol-mediated surfactant 
inhibition; however, serum levels of cholesterol do not affect surfactant composition or the 
severity of lung injury.  In conclusion, elevated cholesterol within surfactant represents a 
mediator of surfactant dysfunction which can impede proper lung function, but SP-A can 
mitigate this form of inhibition.   
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Chapter 1   
1 Introduction and general literature review 
 
1.1 Overview 
 
The primary purpose of the lungs is to facilitate gas exchange between the external and 
internal environment. Specifically, oxygen from the environment diffuses into systemic 
circulation while carbon dioxide diffuses out of the systemic circulation (West, 2005).  
Paramount to the proper function of the lungs is a lipoprotein complex called pulmonary 
surfactant (Possmayer, 2004).  Surfactant is produced endogenously and its primary 
purpose is to reduce surface tensions within the lung to maintain lung compliance and 
prevent alveolar collapse.  These properties help with the lung’s ability to facilitate 
respiration (West 2005).  Impairments in surfactant function have been shown to result in 
lung dysfunction; one such consequence of lung dysfunction is hypoxemia – a potentially 
life-threatening condition wherein a patient is unable to maintain adequate levels of blood 
oxygenation.  Hypoxemia is one characteristic of severe lung dysfunctions such as the 
acute respiratory distress syndrome (ARDS) (Brower et al., 2000; Rubenfeld et al., 2012) 
– one of the main focuses of this thesis. 
 
ARDS is a severe pulmonary disorder characterized by severe hypoxemia, decreased lung 
compliance and bilateral chest infiltrates with no indication of cardiac failure (Brower et 
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al., 2000; Rubenfeld et al., 2012).  These patients ultimately require the use of 
mechanical ventilation (MV) as a supportive therapy to maintain oxygenation when lung 
dysfunction is severe (Lee & Slutsky, 2001).  Common amongst patients with ARDS are 
changes to their pulmonary surfactant system.  As noted above, surfactant is a lipoprotein 
complex found within alveoli and its main purpose is to reduce surface tensions within 
the lungs.  Surfactant is predominantly composed of phospholipids (PL), but also 
contains neutral lipids, of which cholesterol is the major component, and four associated 
proteins: surfactant protein (SP)-A, SP-B, SP-C and SP-D (Possmayer, 1988; Veldhuizen 
et al., 1998; Orgeig & Daniels 2001; Hawgood & Shiffer, 1991; Haagsman & Diemel, 
2001).  Alterations to surfactant’s composition, such as decreased SP-A levels, may 
render surfactant susceptible to biophysical impairment.  Recently, elevated cholesterol 
within surfactant has also been shown to cause surfactant dysfunction (Davidson et al., 
2000; Panda et al., 2004; Gunasekara et al., 2005; Vockeroth et al., 2010); however, it is 
currently unknown how surfactant cholesterol can become elevated.  
 
Given that surfactant cholesterol predominantly originates from the systemic circulation 
(Guthmann, 1997; Orgeig & Daniels, 2001), it may be possible that serum 
hypercholesterolemia affects surfactant cholesterol levels.  Due to the growing 
prevalence of serum hypercholesterolemia in humans, determining whether serum 
cholesterol levels affects surfactant cholesterol levels may identify a potential patient 
population at risk of surfactant inhibition and, ultimately, developing ARDS.  
Furthermore, as mentioned above, SP-A may have important properties in maintaining 
surfactant function despite inhibitory agents; however, it remains to be determined 
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whether the presence of SP-A can mitigate the inhibitory effects of elevated surfactant 
cholesterol levels.         
 
The purpose of this thesis is to determine these two unknown factors regarding surfactant 
cholesterol levels.  Specificaly, chapter two will evaluate whether SP-A is able to 
mitigate the inhibitory effects of high cholesterol in surfactant.  Secondly, chapter 3 will 
explore how systemic levels of cholesterol impact surfactant composition and the 
development of lung injury.  Lastly, chapter 4 will outline specific future experiments 
that can be undertaken to further explore the role of high cholesterol in surfactant.  The 
remainder of chapter 1 will discuss general concepts in lung physiology, surfactant 
biophysics and its role in ARDS and will conclude with the rationales and hypothesis for 
chapters 2 and 3.    
 
1.2 Lung function and structure 
 
The main function of the lungs is to facilitate gas exchange between the environment and 
systemic circulation.  This process allows for carbon dioxide from circulation to diffuse 
out of circulation while oxygen from the environment can diffuse into the circulation in 
order to supply oxygen to tissues and vital organs.  The first step in the process of 
breathing is a process called inspiration (West, 2005).  Inspiration is facilitated by active 
contraction of the diaphragm and the external intercostal muscles of the chest (West, 
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2005).  This process of contraction increases the volume of the chest cavity and causes a 
decrease in the air pressure within the lungs (West, 2005).  At this point, the air pressure 
within the lungs is negative relative to the pressure of the external environment.  This 
negative pressure promotes air to flow from the area with higher pressure (the external 
environment) to the areas of lower pressure (the alveoli) (West, 2005).   
 
Air travels through the mouth and nostrils which direct the air through the trachea and 
flows through the branching pathways of the bronchi and enter smaller, further branching 
bronchioles.  Each of the bronchioles terminate at small, air-filled sacs called alveoli 
which are the sites of gas exchange within the lungs (West, 2005).  Alveoli are able to 
efficiently facilitate gas exchange because of three important characteristics.  First, there 
exists a very thin layer of cells between the air within the lungs and the blood vessels.  
Alveolar thickness is very small measuring 2 μm - 200 nm which reduces the distance 
required for gas to diffuse into circulation (West, 2005).  Secondly, in humans, there are 
approximately 300 million alveoli providing 50 – 100 m2 of surface area where gas 
exchange can occur (West, 2005).  Lastly, each alveolus is surrounded by a network of 
capillaries which ensures a constant and close blood supply.  This association of 
capillaries to alveoli is termed the blood gas barrier (BGB) and it is where carbon dioxide 
can diffuse out from systemic circulation and oxygen from respired air can diffuse into 
circulation (West, 2005).  These three properties of alveoli are important to facilitate 
efficient gas exchange at the BGB. The rate of diffusion across the BGB can be 
calculated by Fick’s law.  In general, Fick’s law states that the rate of transfer of a gas is 
proportional to tissue area and inversely proportional to tissue thickness.  Therefore, since 
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the lungs have a very high surface area and the distance between the epithelium and 
vasculature is very small, the rate of gas exchange within the lungs is very high.   
 
Besides the alveolar properties which ensure efficient gas exchange between the lungs 
and circulation, the ability of alveoli to maintain patency, thereby optimizing surface 
area, throughout respiration is of utmost importance for gas exchange (West, 2005).  
Alveoli are able to remain open, in part due to i) the negative pleural pressure, which 
exists between the exterior of the lungs and the chest cavity, and ii) the reduction of 
surface tension at the air-liquid interface due to the presence of pulmonary surfactant.  
The intricacies of surface tension and the characteristics of surfactant will be discussed in 
the following sections. 
 
1.2.1 Surface tension 
An aqueous layer exists between the alveolar epithelial cells and the air within alveoli 
(Possmayer, 2004).  This forms an air-liquid interface within the lungs and is the site 
where surface tension occurs.  Within the bulk-phase of the liquid, water molecules have 
an equal attractive force to other water molecules immediately surrounding resulting in a 
net attractive-force on that molecule of zero (Figure 1.1A).  However, water molecules 
located immediately at the air-liquid interface have a net attraction into the bulk-phase of 
the liquid due to the lack of water molecules immediately above them (Figure 1.1A).  
This attraction downwards into the bulk phase causes high surface tensions and promotes 
the aggregation of water molecules in order to reduce the overall surface area exposed to 
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the air.  As a consequence of this high surface tension, the tendency within the lungs 
would be for alveoli to collapse thus inhibiting gas exchange.  To reduce this surface 
tension within the lungs, a lipoprotein complex termed pulmonary surfactant is produced 
(Figure 1.1B) (Possmayer, 1988; Goerke, 1998; Possmayer, 2004).  The relationship 
between surface tensions within alveoli and the importance of surfactant can be explained 
further using LaPlace’s Law (Figure 1.2). 
 
LaPlace’s law (Figure 1.2) states that the pressure difference across a given sphere is 
equal to twice the surface tension of the sphere divided by its radius.  Based on this law, 
if the radius of a given sphere is reduced, the pressure gradient increases.  If surface 
tension remained constant through this process the pressure differences across such an 
alveolus would therefore increase causing alveolar collapse (Figure 1.2).  In the normal 
and healthy lung, however, surface tension is significantly reduced as the radius 
decreases, via the biophysical properties of pulmonary surfactant.   
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Figure 1.1 Surface tension within the alveoli without and with surfactant present at the 
air-liquid interface.  In (A), a water molecule is shown in bulk of the liquid phase (2) 
which experiences attractive forces from all directions creating a net-zero force acting on 
the molecule.  Water molecule (1) however has reached the air-liquid interface and 
experiences a net downwards force active on the molecule into the liquid.  In (B), we see 
how surfactant lipids prevents molecule (1) from reaching the air-liquid interface thereby 
reducing the net-downwards force and reducing surface tension. 
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The importance of surface tension and surfactant within the lung is best described in 
premature neonates afflicted with neonatal respiratory distress syndrome (nRDS).  First 
described by Avery and Mead in 1959, premature infants diagnosed with nRDS presented 
with hypoxemia and laboured breathing (Avery & Mead, 1959).  These symptoms were 
attributed to the high surface tension present within their lungs due to surfactant 
deficiency.  To treat this condition, clinicians now administer exogenous surfactant to 
newborns with nRDS before the first breath.  As a result of exogenous surfactant therapy, 
infants with nRDS have significantly improved lung compliance, blood oxygenation and, 
importantly, decreased overall mortality (Enhorning et al., 1985; Robertson et al., 1989).  
The effects of surfactant deficiency and subsequent successes of surfactant therapy in this 
setting emphasize the impact that a functional surfactant system has on proper lung 
function. In this thesis, conditions that alter the surfactant system within the mature lung 
will be addressed. 
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Figure 1.2 Schematic diagram of LaPlace’s Law demonstrating alveolar collapse. The 
difference in pressure across two alveoli can be determined as a relationship between the 
surface tension present within the alveoli (γ) and the alveoli radius (r).  In this scenario 
the alveoli pictured on the left (A) has a larger radius compared to the smaller alveoli (B).  
As a result, the pressure within B is greater than in A.  The consequence of this pressure 
gradient is air within alveoli (B) enters alveoli (A) causing alveoli (B) to collapse. 
 
 
 
(B) 
Alveoli 
(A) 
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1.2.2 Pulmonary surfactant: composition, metabolism and function 
Pulmonary surfactant is an important homeostatic lipoprotein complex formed within 
alveoli (Possmayer, 2004).  Its primary purpose is to reduce the surface tensions within 
alveoli to near 0 mN/m at the end of exhalation.  Proper surfactant composition is crucial 
to the material’s biophysical properties which are necessary for normal lung function.  
The following sub-sections will address surfactant’s composition, metabolism, and 
biophysical functions. Ramifications of surfactant impairment on lung physiology will 
then be discussed. 
 
1.2.3 Surfactant composition 
Surfactant is a lipoprotein complex primarily composed of phospholipids (PL), neutral 
lipids and surfactant associated proteins.  Surfactant composition is highly conserved 
amongst homeothermic mammals (Veldhuizen et al., 1998, Orgeig & Daniels, 2001).  PL 
comprises 80-85% of surfactant by weight, of which 80% is phosphatidylcholine (PC), 
which, in turn is 40-50% in disaturated (dipalmitoylphosphatidylcholine, DPPC) form 
(Possmayer, 1988; Goerke, 1998; Veldhuizen et al., 1998).  DPPC is the key 
phospholipid responsible for the surface tension reducing capabilities of surfactant.  The 
disaturated nature of DPPC molecules allow them to associate tightly together during 
periods of surface area compression.  This property of DPPC will be further examined in 
a subsequent section.  In addition to DPPC, surfactant also contains phosphtidylglycerol 
(PG, 10-15% of PL), phosphatiylethanolamine (PE, 3% of PL) and sphingolmyelin (SM) 
(Veldhuizen et al., 1998). These surfactant PL are thought to enhance the rate of 
adsorption of surfactant.  Lastly, surfactant contains neutral lipids composing 
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approximately 5-10% wt/wt PL (Orgeig & Daniels, 2001).  Within the neutral lipid 
component of surfactant, free cholesterol represents the predominant species (Guthmann, 
1997; Orgeig & Daniels, 2001).  The purpose of neutral lipids within surfactant remains 
uncertain.  However, it must be noted that elevated cholesterol levels within surfactant 
have been shown to cause biophysical dysfunction within the material (Davidson et al., 
2000; Panda et al., 2004; Gunasekara et al., 2005; Vockeroth et al., 2010).  Thus, 
cholesterol levels within surfactant may be a relevant consideration in the setting of 
surfactant alterations in severe lung disorders such as the acute respiratory distress 
syndrome (ARDS).  
 
In addition to the lipids, there are also four specific surfactant-associated proteins: 
surfactant protein (SP)-A, -B, -C and –D.  These four proteins represent 8-10% of 
surfactant by weight and can be categorized into two main types: hydrophobic (SP-B and 
SP-C) and hydrophilic (SP-A and SP-D) (Possmayer, 1988; Goerke, 1998; Haagsman & 
Diemel, 2001).  The smaller hydrophobic SP-B and SP-C molecules are embedded within 
the acyl-tails of surfactant lipids and have an important role in the biophysical function of 
surfactant (Weaver & Conkright, 2001). SP-B knockout mouse models have been shown 
to be embryonic lethal thus emphasizing the protein’s important role within the lungs 
(Clark et al., 1995; Tokieda et al., 1997; Weaver & Conkright, 2001).  Furthermore, 
while SP-C knockout mice are phenotypically normal, in vitro assessments of the 
biophysical function of their surfactant demonstrated surface film instability compared to 
surfactant from wild-type mice (Glasser et al., 2001). Based on these observations, SP-B 
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and SP-C are both crucial proteins to the proper biophysical function of surfactant and 
lung function as well.   
 
With regards to the hydrophilic proteins, SP-A and D are larger, multimeric proteins 
(Goerke, 1998).  SP-A is the most abundant surfactant associated protein and represents 
approximately 5% of surfactant PL by weight, while SP-D represents approximately 1% 
of surfactant PL by weight (Goerke, 1998).  Both SP-A and SP-D belong to the collectin 
family of proteins, thus they both have roles in the innate immune defense of the lung 
(Weaver & Whitsett, 1991).  Specifically, SP-A and SP-D have the ability to opsonise 
bacterial cells for phagocytotic removal by alveolar macrophages (Weaver & Whitsett, 
1991).  Although this concept of innate immunity provided by SP-A and SP-D is an 
important feature of the lungs, the topic is beyond the scope of this thesis; however, many 
excellent reviews on the subject are available (Wright, 1997; McCormack & Whitsett, 
2002; Sano & Kuroki, 2005). Biophysically, SP-A has been shown to enhance the rate at 
which surfactant is able to adsorb at the air-liquid interface (Weaver & Whitsett, 1991).  
However, Korfhagen and colleagues (1996) showed that SP-A null mice were 
phenotypically normal with regards to lung physiology.  Furthermore, the biophysical 
function of surfactant from SP-A null mice was not significantly different compared to 
surfactant containing SP-A.  However, at decreased concentrations of DPPC, surfactant 
from SP-A null mice had impaired ability to reduce surface tensions compared to 
surfactant with SP-A (Korfhagen et al., 1996). Thus, although SP-A may not be 
necessary for surfactant function in the normal lung, SP-A may play an important role in 
maintaining surfactant function when it would otherwise be compromised.   
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The presence of both surfactant lipids and associated proteins within the surfactant film at 
the air-liquid interface are crucial for the biophysical function of surfactant.  With that 
said, the surfactant film itself is not a static complex.  Surfactant continuously undergoes 
stages of metabolism in order to maintain a consistent film at the air-liquid interface in 
order to confer its surface tension reducing capabilities to the lungs. 
 
1.2.4 Surfactant metabolism 
Surfactant is synthesized within type-2 alveolar cells (Figure 1.3).  After surfactant is 
synthesized, the material is stored intracellularly within organelles known as lamellar 
bodies (Mason & Voelker, 1998).  A variety of factors can stimulate the release of 
lamellar bodies from within the alveolar type 2 cell.  For instance, adenosine triphosphate 
may signal the release of surfactant by a protein-kinase A phosphorylation pathway 
(Chandler & Fisher, 1999; Rooney, 2001).  Furthermore, adenosine, itself a 
neuronaltransmitter, may also stimulate surfactant secretion (Chandler & Fisher, 1999; 
Rooney, 2001).  Lastly, repeated stretching of type-2 cells during respiration also 
stimulates the fusion of lamellar bodies to the type-2 cellular membrane thereby releasing 
surfactant into the alveolar space (Mason & Voelker, 1998).  Once in the alveolar space, 
lamellar bodies unwind and form a structure known as tubular myelin (Possmayer, 2004).  
Tubular myelin contains all of surfactant’s lipids and associated proteins with the 
exception of SP-D.  Tubular myelin is able to form a surface-active film at the air-liquid 
interface which is capable of reducing surface tensions to near 0 mN/m at.  This reduction 
in surface tension is necessary to optimize lung compliance (described via LaPlace’s 
Law) thereby preventing alveolar collapse and decreases the effort required to breathe.  It 
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is believed that tubular myelin also acts as a reservoir from which a surfactant film can be 
formed.  This concept is important during inhalation when the surface area is stretched as 
surfactant lipids and proteins are able to re-insert themselves into the film in order to 
maintain functional surfactant film. 
 
Experimentally, extracellular, or alveolar, surfactant can be obtained via whole-lung 
lavage and can be separated into two distinct surfactant sub-fractions by high speed 
centrifugation: a large aggregate (LA) pellet (Veldhuizen et al., 1993) and a small 
aggregate (SA) supernatant (Wright 1990; Brackenbury et al., 2002).  The LA pellet, 
containing tubular myelin, has been shown capable of reducing surface tensions in vitro 
and improve lung physiology when given to surfactant depleted animals in vivo.  The SA 
sub-fraction contains small lipid vesicles and SP-D, although, in vitro experiments have 
shown that the SA sub-fraction of surfactant is not as surface active as LA (Yamada et 
al., 1990; Brackenbury et al., 2002).   
 
During respiration, repeated changes to alveolar surface area occurs with each breath, 
causing surfactant to convert from its surface active LA component to the non-surface 
active SA component.  Using intratracheally instilled and radiolabelled LA, Wright 
(1990) showed that in vivo, LA is converted into SA and larger changes in lung surface 
area corresponded with increased conversion of LA to SA.  SA were then taken-up by the 
type-2 cells within alveoli where it can be recycled back into lamellar bodies or degraded.  
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Overall, it has been estimated that the process of producing and recycling surfactant takes 
approximately 7 – 10 hours (Jacobs et al., 1982).   
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Figure 1.3 Representation of surfactant metabolism.  Surfactant is produced within type-
2 alveolar cell and stored in an organelle termed lamellar bodies.  These organelles are 
exocytosed where they become unravel to become tubular myelin structures.  These act 
as surfactant reservoirs and during respiration, functional surfactant in the form of large 
aggregates (LA) adsorb to the air-liquid interface to form a functional surfactant film.  
Repeated surface area changes during respiration changes LA into the non-functional 
small aggregate (SA) sub-fraction which can be taken-up by the type-2 cell and recycled 
back into LA or degraded. 
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1.2.5 Biophysical function of surfactant 
As mentioned previously, the primary purpose of surfactant is to reduce the surface 
tension within the lungs.  The ability of surfactant to reduce the surface tension can be 
divided into two distinct stages: 1) adsorption and 2) compression and expansion cycles.  
These two processes describe the ability of surfactant to initially form a film at the air-
liquid interface and its ability to further reduce the surface tension when lung volumes are 
reduced when the film is compressed at the end of exhalation.  These two properties will 
be further discussed in subsequent sections. 
 
1.2.5.1 Adsorption 
Adsorption is the process in which surfactant lipids and associated proteins are able to 
form a surface-active film at the air-liquid interface of alveoli (Walters et al., 2000; 
Possmayer, 2004).  Tubular myelin released from type-2 alveolar cells is able to move 
through the hypophase towards the air-liquid interface.  Since PL are amphipathic, they 
are able to orient themselves at the air liquid interface with their hydrophobic acyl-tails 
directed towards the air-space and their hydrophilic polar head-group towards the 
hypophase.  In this orientation, the hydrophilic heads of PL are able to displace water 
molecules. 
 
Although primarily composed of lipids, this process requires the presence of the 
surfactant-associated proteins to facilitate rapid adsorption.  In vitro studies have shown 
that surfactant films composed of lipids alone cannot rapidly adsorb to the air-liquid 
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interface without the presence of SP-B and/or SP-C (Possmayer, 2004).  Specifically, in 
1990, Yu and Possmayer showed that in vitro, surfactant films composed of DPPC/PG 
were able to adsorb more rapidly when SP-B and SP-C were added to surfactant.  
Additionally, while SP-A is not necessary to facilitate adsorption, its presence in 
surfactant enhances the overall rate of adsorption of the material in conjunction with SP-
B (Hawgood et al., 1987; Rodriguez-Capote et al., 2001).  This ability for surfactant to 
rapidly form a surface active film is crucial to its ability to subsequently reduce surface 
tensions within the lung during compression.    
 
1.2.5.2 Compression/expansion of surfactant films 
As the alveolar surface area decreases during exhalation, the surfactant film undergoes a 
process termed “compression” wherein the surfactant associated proteins and lipids act in 
conjunction to reduce the surface tensions within alveoli to near 0 mN/m.  With regards 
to the surfactant associated proteins, SP-B and –C are highly associated with the PL film 
due to their hydrophibocity (Weaver & Conkright, 2001).  They are thought to link 
surfactant lipids at the air-liquid interface to a surfactant reservoir directly underneath the 
film in order to facilitate the re-insertion of surfactant lipids to the air-liquid interface 
(Schurch et al., 1995; Veldhuizen et al., 2001).  This is important during inhalation as 
alveolar surface area expands and the insertion of PL to the air-liquid interface is required 
in order to maintain a concurrent lipid film.  In contrast to SP-B and SP-C, the role of SP-
A during compression is less well known.   
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During compression, PL molecules become tightly packed and it is believed that it is this 
tight lateral organization of PL which is responsible for reducing the surface tension to 
near 0 mN/m.  It must be noted, however, that not all lipids are capable of forming a 
stable surface active film upon compression.  For instance an in vitro study conducted by 
Hawco and colleagues (1981) utilized surfactant films comprised of only PC.  It was 
observed that this film had an impaired ability to attain low surface tensions upon 
compression.  It was determined that the unsaturated nature of PC molecules limited the 
film’s ability to attain low surface tension values.  Specifically, the film composed of PC 
was able to attain a minimum surface tension of 20 mN/m which is higher than films with 
DPPC which have been shown capable of attaining minimum surface tensions of 0 mN/m 
during compression (Ingenito et al., 1999).   
 
1.2.6 Experimental techniques to measure surfactant function 
The ability for surfactant to reduce surface tensions to very low values within alveoli 
during periods of adsorption and compression are essential to the proper function of the 
lungs.  In order to examine the role of specific components of surfactant, including 
associated proteins such as SP-A, neutral lipids and cholesterol, in the biophysical 
function of surfactant, we have utilized various in vitro and in vivo approaches.  Relevant 
to this thesis is a discussion of one such in vitro technique, the captive bubble 
surfactometer (CBS) (Figure 4) and an in vivo surfactant depleted animal model. 
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Figure 1.4 Schematic representation of the chamber used in the captive bubble 
surfactometer (CBS).  The surfactant sample of known concentration is introduced with a 
micropipette via the sample induction port.  The surfactant rises to the top of the chamber 
towards the bubble due to its high buoyancy in the sucrose buffer.  The shape of the 
bubble can be controlled by a motor which moves the plunger up and down.  As the 
bubble changes in volume, changes in surface area can be calculated by determining the 
bubble’s height:width ratio.   
 
  
 
 
 
21 
 
1.2.6.1 In vitro assessment of surfactant function: captive bubble 
surfactometer 
The CBS, designed by Schurch, is an apparatus which measures the surface tension 
reducing capability of surfactant preparations through stages of adsorption, compression 
and expansion cycles (Schurch, 1989).  It consists of an air-tight chamber containing a 
sucrose gradient buffer wherein an air bubble approximately 8 mm in diameter is 
introduced (Figure 1.4).  The bubble rises to the top of the chamber and comes to rest at 
a hydrophilic agar surface.  Surfactant preparations are then introduced into the chamber 
and adsorbs to the air-liquid interface of the air bubble and surrounding liquid.   
 
To determine the surface tension reducing capabilities of the surfactant, a computer 
controlled piston decreases or increases the volume of the bubble within the chamber.  
For example, changes in chamber volume influence changes in chamber pressure causing 
the bubble to either expand or contract in volume.  This change in bubble volume is 
meant to mimic the changes in alveolar volume during inhalation and exhalation.  To 
determine the surface tension during these dynamic compression-expansion cycles, the 
shape of the bubble is recorded by a digital camcorder and the height:width ratio of the 
bubble can be used to calculate the volume and area of the bubble which corresponds to 
the surface tension of the surfactant film.    Overall, the CBS allows for accurate and 
rapid assessment of a surfactant samples ability to adsorb and attain minimum surface 
tensions during compression.  The assessment of these biophysical properties of 
surfactant have been important in determining the functionality of patients with severe 
lung disorders such as the acute respiratory distress syndrome (ARDS).   
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While the CBS provides experimenters with a rapid and accurate quantitative tool by 
which to measure surfactant’s biophysical properties, the in vitro nature of the apparatus 
cannot assess the physiological consequences of various surfactant preparations.  To 
address how various surfactant preparations affect lung function and physiology, the use 
of surfactant-depleted animal models can be used. 
 
1.2.6.2 Surfactant depleted animals 
Surfactant depleted animals provide a model to study the effects various surfactant 
preparations on lung physiology.  Lachmann and colleagues (1989) used surfactant 
depleted rabbits to study the pathophysiology ARDS  It was shown that adult rabbits 
made surfactant depleted via repeated saline whole-lung lavages mimicked the 
physiological signs of ARDS including increased peak inspiratory pressure (PIP) and 
significantly reduced arterial oxygenation (PaO2) indicting the development of 
hypoxemia (Lachmann et al., 1989).  With the use of surfactant depleted animals, it 
became possible to determine the efficacy of exogenous surfactant preparations on lung 
function.  For example, Lewis and colleagues (1993) used surfactant deficient adult sheep 
to show that the application of exogenous surfactant can improve the PIP and PaO2 of the 
surfactant depleted sheep.  Importantly, surfactant deficient animals can also be used to 
determine how surfactants afflicted with different forms of inhibition can affect lung 
function.  For instance, in 2007, Keating and colleagues showed that surfactant deficient 
rats treated with exogenous surfactant reconstituted with cholesterol had decreased PaO2 
as compared to rats treated with surfactant without cholesterol.   
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Overall, the use of the CBS allows for the quantification of surfactant’s surface tension 
reduction capabilities.  Meanwhile, the use of surfactant depleted animals allows 
researchers to observe the effects of various surfactant preparations on lung physiology.  
Both of these investigational tools have been used to ascertain whether changes to 
surfactant’s biophysical function are present in the surfactant collected from patients with 
various forms of lung injury such as ARDS.   
 
1.3 Acute respiratory distress syndrome 
 
Although the definition and criteria of the acute respiratory distress syndrome (ARDS) 
has been re-evaluated several times over the years, the hallmarks of the disorder has 
remained the same: decreases in lung compliance, severe hypoxemia and bilateral chest 
infiltrates not due to cardiac failure (Bernard et al., 1994; Reubenfeld et al., 2012).  The 
development of ARDS can occur from both indirect and direct insults to the lung (Ware 
& Matthay, 2000).  Indirect insults including sepsis, trauma and multiple blood 
transfusions can promote systemic inflammation which can also affect the lungs.  Direct 
insults to the lungs include smoke inhalation, gastric acid aspiration and pneumonia and 
these factors directly impair the lung’s epithelium and surfactant system decreasing 
compliance and oxygenation.  Clinically, ARDS presents as severe hypoxemia and the 
severity of ARDS is reflected in the overall level of oxygenation in arterial circulation 
(Bernard et al., 1994; Reubenfeld et al., 2012).   
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1.3.1   Alterations to surfactant composition in ARDS 
Studies investigating the biophysical properties of surfactant collected from patients with 
ARDS have shown that their surfactant has altered composition and impaired surface 
tension reducing properties (Gunther et al., 1996).  Unlike neonates afflicted with nRDS, 
the onset of ARDS is not predicated on surfactant deficiency.  Indeed, surfactant from 
patients with ARDS has been shown to have a complex array of changes to surfactant’s 
composition and biophysical dysfunction of the material (Gregory et al., 1991; Gunther et 
al., 1996).  Changes to surfactant’s PL profile, increased conversion of LA to SA and the 
presence of serum proteins in surfactant have been observed in lavage collected from 
ARDS patients (Cockshutt et al., 1991; Veldhuizen et al., 1995; Gunther et al., 1996; 
Lewis & Veldhuizen, 2002; Lewis & Maruscak, 2006).  Recently, it has also been 
suggested that elevated levels of cholesterol within surfactant contribute to surfactant 
dysfunction and may play a role in the development of ARDS. These alterations to 
surfactant may contribute to the overall biophysical impairment of the material and 
mediate the development of ARDS.   
 
Changes to surfactant’s PL profile and associated protein levels have been identified in 
patients with ARDS when analyzing lavage material collected from their lungs.  
Specifically, it has been reported that patients with ARDS have a decreased amount of 
DPPC, PC and PG and an increase in the amount of PE, SM and lyso-
phosphatidylcholine (lyso-PC) (Pison et al., 1987; Gunther et al., 1996; Schmidt et al., 
2007).  Given that DPPC is the PL primarily responsible for the surface tension reducing 
properties of surfactant, decreases in DPPC’s concentrations may affect the overall 
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biophysical function of surfactant.  With regards to the surfactant associated proteins, it 
has been observed that SP-A, SP-B and SP-C levels are also reduced in surfactant 
obtained from ARDS patients and this decrease in surfactant associated proteins may be 
due to alterations in type-2 cell metabolism or, possibly, elevated proteolytic activity (Lee 
et al., 1981; McGuire et al., 1982).  As mentioned previously, Korfhagen and colleagues 
(1996) were able to show that SP-A null mice were phenotypically normal, but their 
surfactant was more sensitive to inhibition as compare to surfactant with SP-A.  
Furthermore, serum-protein mediated surfactant inhibition has also been shown to be 
mitigated by the presence of SP-A (Cockshutt et al., 1991).  Therefore, while SP-A is not 
necessary for proper lung function under healthy conditions, its role in mitigating 
surfactant inhibition when the system is under duress highlights the importance of SP-A 
and the decreases in SP-A levels in ARDS patients may render their surfactant to be more 
susceptible to inhibition.  Taken together, these observations show that changes to 
surfactant’s PL and protein composition affects surfactant’s function and may contribute 
to the development of ARDS. 
 
Additionally, the alterations to the composition of surfactant’s sub-fractions have also 
been observed in the lavage of patients with ARDS.  For example, Veldhuizen and 
colleagues (1995) showed that lavage from ARDS patients showed an increased ratio of 
SA:LA as compared to lavage from non-ARDS patients (0.48 vs. 0.20 respectively).  
Additionally, Gunther and colleagues (1996) also showed that in lavage collected from 
patients with ARDS contains 36% LA (as a percentage of total surfactant) as compared to 
lavage from healthy lungs which contain between 60-75% LA.  Given that in vitro 
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experiments have shown that SA is less biophysically active than LA (Brackenbury et al., 
2002), an increased SA/LA ratio suggests that surfactant’s surface tension reducing 
capability may be compromised. Interestingly, the increased conversion of LA into SA 
may be a consequence of mechanical ventilation (MV) (Veldhuizen et al., 1996; Ito et al., 
1997).  The role of MV in increasing the SA/LA ratios will be discussed in more detail in 
a following section. 
 
Although not natural components of surfactant, the presence of serum proteins within 
lavage recovered from patients with ARDS due to leakage into the airspace from the 
serum, also represent agents which can impair surfactant function (Ware & Matthay, 
2000).  Due to the close and extensive proximity of alveoli to the systemic circulation, 
insults compromising the barrier between the two regions can cause an influx of serum 
proteins during pulmonary edema.  Studies have shown that serum proteins such as 
hemoglobin, albumin and fibrinogen can impair the surface-tension reducing capability 
of surfactant by physically interfering with PL from adsorbing to the air-liquid interface 
(Seeger et al., 1985; Cockshutt et al., 1990).  This interference ultimately results in 
deficiencies in surfactant’s ability to achieve low surface tensions within the lung thus 
affecting compliance.   
 
Recently, studies have also shown that elevations in the neutral lipid component of 
surfactant, of which cholesterol is the major component, is also present in surfactant 
obtained from patients with ARDS.  For example, Markat and colleagues (2007) showed 
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that lavage from patients afflicted with ARDS had twice the amount of neutral lipid as 
compared to lavage obtained from healthy subjects.  Additionally, in vitro studies 
analyzing the biophysical properties of surfactant reconstituted with elevated levels of 
cholesterol has shown that the material is unable to achieve low surface tensions 
compared to surfactant with physiological concentrations of cholesterol (Gunasekara et 
al., 2005; Keating et al., 2007).  The contribution of cholesterol to the biophysical 
impairment of surfactant is an important concept for the purposes of this thesis.  To that 
end, further detail regarding cholesterol mediated surfactant dysfunction will be 
discussed in subsequent sections as it applies to injuries sustained due to MV and the 
contribution of serum levels of cholesterol as well. 
 
1.3.2 Mechanical ventilation 
MV is a necessary intervention in patients with ARDS.  Without the use of MV to 
maintain oxygenation, it has been estimated that the mortality rate of patients afflicted 
with ARDS would approach 90% (Reubenfeld, 2003).  Despite the necessity of MV, MV 
itself has been shown to propagate the development of further lung injury (Webb & 
Tierney, 1974; Dreyfuss & Saumon, 1998; Brower et al., 2000; Veldhuizen et al., 2001).  
The contribution of MV to the development of further lung injury can be attributed to two 
main causes: 1) shear forces within alveoli and 2) over-distension of alveoli epithelium 
(Slutsky, 1999).  Shear forces occur during repeated collapse and opening of alveoli 
during ventilation.  Recent advance in ventilation techniques have demonstrated that the 
use of positive end expiratory pressure (PEEP), or a volume of air left in the lungs after 
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exhalation, maintains alveolar patency.  In effect, PEEP reduces the degree of repeated 
alveolar collapse and recruitment.   
 
The importance of over-distension of alveoli due to MV in the progression of lung injury 
was investigated in a large multi-centered clinical trial conducted by the Acute 
Respiratory Distress Syndrome Network (ARDSnet) in 2001.  In this study, it was 
demonstrated that ARDS patients placed on MV with PEEP and low tidal volumes (6 
mL/kg) had significantly lower mortality (31%) than ARDS patients placed on MV with 
higher tidal volumes (12 mL/kg, 40% mortality).  This observation demonstrates how 
specific ventilator parameters can influence the progression of lung injury and, 
ultimately, mortality.  Given the importance of MV for patients with ARDS and the 
associated damages that MV can also cause to the lung, research has been undertaken to 
better understand how MV contributes to the development of lung injury.  One method 
has been to use animal models placed on high-stretch mechanical ventilation to develop 
lung injury.  These animals are considered to be afflicted with ventilator-induced lung 
injury (VILI). 
 
1.3.3 Animal models of VILI 
As discussed previously, MV can progress the severity of lung injury in patients due to 
repetitive alveolar collapse and over-distension of the alveolar epithelium (Slutsky, 
1999).  These factors can be mimicked in animal models by utilizing ventilation 
strategies with high tidal volumes and zero PEEP.  The high tidal volume ensures that 
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alveoli become over-distended, and zero PEEP promotes alveolar collapse.  Although use 
of high tidal volumes and zero PEEP are effective in developing VILI in animal models, 
one limitation is these settings do not reflect clinical realities.  Patients with severe lung 
injuries are typically ventilated with low tidal volumes with additional PEEP to minimize 
lung damage (Brower et al., 2001).  Furthermore, animal studies of VILI are conducted 
over the course of a few short hours as compared to patients who may require ventilation 
for days.  Nevertheless, several studies have shown that similar changes are present in rat 
models of VILI and patients with lung injuries such as ARDS including decreased 
oxygenation (Veldhuizen et al., 2002; Maruscak et al., 2008), altered surfactant 
composition (Verbruggae et al., 1998; Maruscak et al., 2008) and diminished biophysical 
properties (Panda et al., 2004).  
 
For instance, alterations the percentage of LA has been shown in models of VILI 
(Maruscak et al., 2008).  Ito and colleagues (1997) observed that large changes to 
alveolar surface area due to high tidal volume ventilation resulted in increased conversion 
of LA to SA in vivo (Veldhuizen et al., 1996; Ito et al., 1997).  This observation has been 
further confirmed with in vitro experiments indicating that increased changes to surface 
area promotes the conversion of LA to SA (Veldhuizen et al., 2000).  These observations 
indicate that the observed elevation in SA/LA ratio in surfactant from ARDS patients 
may be as a direct result of MV. 
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1.3.4 Surfactant cholesterol and VILI 
One important change in surfactant composition observed in animals with VILI are 
elevations to the amount of cholesterol within surfactant.  Using a VILI model in rats, 
Maruscak and colleagues (2008) observed that the surfactant of animals with VILI had 
significantly increased cholesterol levels as compared to rats without lung injury.  
Importantly, Maruscak and colleagues also observed that the elevations in surfactant 
cholesterol levels were present in rats placed on high-stretch ventilation prior to the 
physiological manifestations of VILI such as increased PIP and decreased PaO2.  This 
observation indicates that changes to surfactant composition, such as elevated cholesterol 
levels, may occur early and potentially contributes to the development of VILI.     
 
In a follow-up study, Vockeroth and colleagues (2010) showed that, in vitro, the 
biophysical properties of surfactant obtained from rats with VILI was improved 
following sequestration of cholesterol from the material.  Moreover, reconstitution of 
high levels of cholesterol into surfactant resulted in decreased surface tension reducing 
properties of the material.  Overall, elevated levels of cholesterol within surfactant may 
represent another mechanism of surfactant inhibition.  Unlike serum protein mediated 
inhibition, however, cholesterol is an inherent component of surfactant and it is currently 
unknown how cholesterol levels become augmented within surfactant.  One consideration 
into the potential mechanisms which elevate cholesterol levels within surfactant may be 
related to the levels of cholesterol within the body’s circulatory system.  
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1.4 The role of serum cholesterol  
 
As mentioned previously, surfactant composition includes approximately 4-7% wt/wt PL 
neutral lipids of which cholesterol is the major component.  In an effort to determine the 
origin of cholesterol within surfactant, a study was conducted in 1995 by Orgeig and 
Daniels which utilized radio-labeled cholesterol injected into the tail-vain of rats.  Upon 
obtaining the alveolar lavage of these rats, Orgeig and Daniels observed that the 
overwhelming constituency (~99%) of cholesterol within alveoli was radio-labeled.  
Furthermore, the presence of both LDL and vLDL receptors on the basolateral membrane 
of alveolar type-2 cells suggest a mechanism by which facilitate the uptake of cholesterol 
from serum (Guthmann et al., 1997).  These observations indicate that alveolar 
cholesterol levels predominantly originate from the serum.    Since surfactant cholesterol 
predominantly originates from the serum, it has been postulated that serum levels of 
cholesterol may affect the amount of cholesterol present within surfactant.   
 
A study conducted by McCrae and colleagues in 2008 was conducted to determine 
whether high serum cholesterol levels would affect surfactant levels of cholesterol and, 
ultimately, surfactant function.  McCrae and colleagues placed mice on a high cholesterol 
diet for a period of 16 weeks.  At the end of this dietary period, lavage analysis showed 
that mice fed a high cholesterol diet had a significantly higher proportion of cholesterol 
as compared to the lavage of mice fed a standard diet (0.26±2.83 mol% vs. 7.84±1.44, 
respectively).  To test the effect of elevated cholesterol within surfactant, McCrae and 
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colleagues utilized capillary surfactometry.  In this test, surfactant was pipetted into a 
small capillary tube.  Pressurized air was then injected through the tube for a period of 
120 seconds in order to pierce the meniscus of surfactant and to measure the overall 
patency of surfactant present.  Their results showed that surfactant containing elevated 
cholesterol was less patent than the surfactant with normal levels of cholesterol.  This 
decreased patency indicated that the surfactant with high cholesterol was less stable than 
surfactant with normal levels of cholesterol.  Therefore, this study indicated that high 
cholesterol in surfactant may render the material less capable of forming a stable surface-
active film.  Despite this finding, however, the observations from this study have not 
been reported in any other animal models.  Therefore, it is currently unknown whether 
the effects of diet-induced serum hypercholesterolemia observed in this particular study 
will translate to other animals such as rats and, ultimately, humans.     
        
A clinical study conducted by O’Neal and colleagues (2011) attempted to determine the 
rates of developing ARDS in critically ill patients based on their prior use of cholesterol 
lowering drugs – HMG-CoA inhibitors or “statins”.  Their study analyzed the 
development of ARDS in 575 critically ill patients admitted to a medical or surgical ICU.  
The results of this study indicated that the patients who had taken statins prior to 
hospitalization had significantly reduced chance of developing sepsis or ARDS as 
compared to patients not placed on statins.  Despite the findings of this study, it is unclear 
whether the observed decrease in development of ARDS in patients was due to the 
cholesterol lowering effects of statins or due to the known anti-inflammatory effects of 
the drugs themselves.   
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Recently, a study conducted by Yamashita and colleagues (2012) attempted to determine 
whether serum hypercholesterolemia affected the severity of lung injury.  In their study, 
Yamashita and colleagues used an apolipoprotein-E (ApoE) null mice as a model of 
serum hypercholesterolemia.  These mice were then treated with hydrochloric acid (HCl) 
to develop acid-induced lung injury – a model of gastric acid-aspiration induced lung 
injury.  Gastric acid-aspiration induced lung injury represents the second leading cause of 
ARDS worldwide.  In the study conducted by Yamashita and colleagues, the ApoE null 
mice were observed have increased pulmonary inflammation as compared to wild-type 
mice.  These findings indicate that serum hypercholesterolemia may also play a role in 
promoting the development of more severe lung injury.  However, due to the use of 
genetically modified mice it remains to be determined whether the increased pulmonary 
inflammation can be truly attributed to serum hypercholesterolemia, or as a result of 
ApoE deficiency.   
 
Based on the aforementioned studies, it is evident that elevated cholesterol within 
surfactant can cause biophysical impairments of the material and may render the 
surfactant film less stable at the air-liquid interface.  Furthermore, serum 
hypercholesterolemia may render patients more susceptible to the development of more 
severe ARDS.  However, due to the limitations inherent within these studies, there is still 
a lack of conclusive evidence linking serum hypercholesterolemia in and of itself to the 
development and ultimate severity of ARDS.  Due to the ever-growing prevalence of 
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serum hypercholesterolemia in humans, determining whether there is a connection 
between serum hypercholesterolemia and surfactant function is an important 
consideration.  Investigating this potential relationship may reveal a patient population at 
greater risk of developing lung injuries such as ARDS and this knowledge can be used to 
prescribe more specific and precise interventions to reduce the risk of developing ARDS.        
  
1.5 Rationale and hypotheses 
 
The lungs are an essential organ responsible for maintaining life by facilitating gas 
exchange (West, 2005).   The biophysical properties of pulmonary surfactant are 
important to the lung’s ability to function and impairments to surfactant’s surface tension 
reducing capabilities lead to the development of severe lung injuries such as ARDS.  
Surfactant inhibition can occur as a result of a multitude of changes to its composition 
including an altered lipid profile, changed LA/SA ratios, PL oxidation and the presence 
of inhibitory agents such as serum proteins.  Recent studies have also shown that elevated 
cholesterol can inhibit surfactant function.  Importantly, although SP-A has been shown 
capable of mitigating the effects of surfactant inhibition due to decreased DPPC 
concentrations, PL oxidation, and serum protein-mediated inhibition, it is currently 
unknown whether SP-A can also mitigate the effects of cholesterol-mediated surfactant 
inhibition.  Furthermore, there is evidence supporting that serum hypercholesterolemia 
may affect surfactant cholesterol levels as well as increase the propensity to develop 
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more severe ARDS.  It is currently unknown, however, whether diet-induced serum 
hypercholesterolemia will affect the severity of various forms of lung injury. 
 
In the first data chapter, we explored the effects of high cholesterol levels in surfactant 
and whether SP-A can mitigate its effects.  We explored this by using the CBS to 
determine the biophysical properties of surfactant with high cholesterol with and without 
SP-A and in vivo by administering exogenous surfactant with various levels of 
cholesterol with and without SP-A to surfactant depleted rats.  Given SP-A’s ability to 
mitigate serum-protein mediated surfactant dysfunction and ability to maintain surfactant 
function even with decreased PL concentrations, SP-A may be able to also mitigate the 
inhibitory effect of high surfactant cholesterol.  The data gathered from this experiment 
will shed insight into the mitigating effects of SP-A and the effects of high cholesterol in 
surfactant on physiological data such as blood oxygenation. 
 
In the second data chapter, our objective was to determine whether diet-induced serum 
hypercholesterolemia will cause changes to surfactant composition and predispose the 
development of more severe ARDS.  Since the majority of surfactant cholesterol is taken-
up from systemic circulation, elevations in the degree of cholesterol in the blood may 
influence surfactant cholesterol levels as well. To explore this, we placed rats on a high 
cholesterol diet and determined the degree of physiological injury and changes to their 
surfactant composition in three different forms of lung injury: VILI, acid-aspiration and 
surfactant depletion.   
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This study has two hypotheses.  First, it was hypothesized that elevated cholesterol in 
surfactant will cause impairment to the material’s biophysical properties and affect lung 
physiology, but the addition of SP-A will mitigate these results.  Secondly, it was 
hypothesized that diet-induced hypercholesterolemia will affect surfactant composition 
and result in the development of more severe ARDS.   
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Chapter 2  
2 SP-A mitigates cholesterol-mediated surfactant 
inhibition and improves the oxygenation in surfactant 
depleted rats. 
 
2.1 Introduction 
 
Pulmonary surfactant is a lipoprotein complex formed within alveolar type-2 cells and 
secreted into the alveolar space which acts to reduce surface tensions at the alveolar 
surface (Possmayer et al., 1984; Goerke, 1998; Possmayer, 2004).  Surfactant is 
composed of 80-90% phospholipids, of which dipalmitoylphosphatidylcholine (DPPC) is 
the major component, 5-10% neutral lipids, of which cholesterol is the major constituent, 
and 5-10% surfactant associated proteins (Veldhuizen et al., 1998; Postle, 2001; 
Possmayer, 2004).  Surfactant released into the alveolar space, termed large aggregate 
(LA), quickly adsorbs to the air-liquid interface where it forms a surface active film 
(Possmayer, 2004). As lung surface area decreases during exhalation, the surfactant film 
undergoes compression which reduces the surface tension to near 0 mN/m (Possmayer, 
2004).  This ability of surfactant to reduce surface tension prevents alveolar collapse, 
maintains compliance of the lungs and reduces the effort required to breathe (Possmayer, 
2004).   
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Patients afflicted with lung injuries, such as the acute respiratory distress syndrome 
(ARDS), have dysfunctional surfactant (Gregory et al., 1991; Gunther et al., 1996; 
Gunther et al., 2001).  The causes for dysfunction of the material include alterations to 
the lipid composition, reduction in the surfactant associated proteins and the presence of 
inhibitory agents (Cockshutt et al., 1990; Seeger et al., 2001; Veldhuizen et al., 1995; 
Gunther et al., 1996).  One such agent that has been investigated is the presence of serum 
protein in the lungs which can occur as a result of pulmonary edema (Ware & Matthay, 
2000).  Proteins, such as albumin and fibrinogen interfere with surfactant’s ability to 
form a film at the air-liquid interface via competitive inhibition (Cockshutt et al., 1990; 
Possmayer, 2004; Da Silva et al., 2005).  This results in increased surface tension within 
the lung and contributes to the decreased oxygenation and reduced lung compliance.  
Recently, the presence of elevated cholesterol has also been implicated as a mechanism 
for surfactant inhibition (Davidson et al., 2000; Panda et al., 2004; Gunasekara et al., 
2005; Vockeroth et al., 2010).  Mechanically ventilated rats with lung injury were shown 
to have an elevated proportion of cholesterol within their surfactant (Maruscak et al., 
2008).  Further in vitro investigation revealed that this surfactant had dysfunctional 
biophysical properties which could be restored by removal of cholesterol (Vockeroth et 
al., 2010). Whereas inhibition of surfactant by serum proteins has been studied 
extensively, cholesterol-mediated inhibition of surfactant’s biophysical function is a 
relatively recent discovery which requires further examination.  
 
One aspect that has been examined in the context of serum protein inhibition is the 
protective role of surfactant protein-A (SP-A) (Cockshutt et al., 1990).  This protein has 
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been shown to mitigate serum protein-mediated surfactant dysfunction by enhancing 
surfactant’s ability to adsorb to the air-liquid interface. However, unlike serum proteins, 
cholesterol is an integral component of surfactant therefore its mechanism of inhibition is 
different than that of serum protein.  It is currently unknown if SP-A has the ability to 
mitigate cholesterol-mediated dysfunction. Based on this information, the purpose of this 
study was to delineate the effects of elevated cholesterol on the biophysical function of 
surfactant and the effects of SP-A on this material.  To investigate these topics, we tested 
the biophysical function of human surfactant reconstituted with various levels of 
cholesterol with and without SP-A in vitro in a captive bubble surfactometer (CBS).  
Additionally, to determine the effects of elevated surfactant cholesterol and SP-A on lung 
function, we administered exogenous surfactant reconstituted with 5 and 20% cholesterol 
with and without SP-A to surfactant depleted rats and assessed their physiology.  It was 
hypothesized that elevated surfactant cholesterol levels would impair the biophysical 
properties of the material leading to decreased lung function, but the presence of SP-A 
could mitigate these effects.     
 
2.2 Methods 
 
2.2.1 Surfactant and SP-A collection from human proteinosis 
patient 
Alveolar proteinosis surfactant was obtained via a whole lung lavage after obtaining 
informed consent. Briefly, the patient was anesthetized and intubated using a dual lumen 
endotracheal tube in order to ventilate each lung independently. Whole lung lavage was 
49 
 
then performed on the left lung and the lavage material was processed immediately to 
obtain Surfactant LA and SP-A from the lavage material.  
 
Immediately following lung lavage procedures, samples were centrifuged for 10 minutes 
at 150g to remove cellular debris. (Veldhuizen et al., 1996)  The supernatant was 
centrifuged at 40,000g for 15 minutes to obtain a pellet of the LA sub-fraction of 
surfactant. The LA pellet was re-suspended in 150mM NaCl and frozen at -20
o
C until 
further use. The amount of LA was analyzed after a chloroform extraction via a 
phospholipid-phosphorus analysis.  Briefly, aliquots LA samples were added to a solution 
containing 1 mL ddH2O, 1 mL methanol and 2 mL chloroform.  This mixture was then 
centrifuged at 150 g for 10 mins to separate the aqueous and organic solvent layers.  The 
organic solvent layer was extracted and dried-down via exposure to O2 gas in a 37°C 
water bath until the liquid chloroform had evaporated.  The remaining solute was ashed 
on a hot-plate after which 1 mL of 1 N HCl was added.  Then, the samples were then 
placed into a heating block at 100°C for 15 mins.  Malachite green dye was added to all 
surfactant samples and the resulting colour was analyzed on a plate reader.     
 
Human SP-A was purified using a similar method as previously described by Haagsman 
et al (1989).  Briefly, to purify SP-A, lavage obtained from human alveolar proteinosis 
patient was centrifuged at 6500 rpm for 30 mins.  The supernatant was discarded and the 
pellet was suspended in re-suspended butanol.  The solution was then centrifuged at 6500 
rpm for 30 mins and then dried with nitrogen gas.  Following, the pellet was 
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homogenized in 20 mM n-octyl-B-D-glucopyranoside in 10 mM HEPES (pH 7.4) and 
then centrifuged at 200,000g for 30 mins.  The supernatant was discarded and the 
remaining pellet was resuspended in n-octyl-B-D-glucopyranoside and was centrifuged 
once again at 200,000g for 30 mins.  The resulting pellet was then re-suspended in 5mM 
Tris and transferred to a dialysis membrane over night.  The next day, the sample was 
centrifuged at 200,000g for 30 mins.  Supernatant was aliquoted and stored at -20
o
C. 
 
2.2.2 Human proteinosis surfactant cholesterol depletion and 
reconstitution 
Cholesterol depletion was done via lipid extraction of crude LA by the method described 
by Bligh & Dyer (1959).  First, the sample was shell-dried with nitrogen gas then re-
suspended with 20 mL of acetone which was then centrifuged at 150g for 15 mins. 
Following centrifugation, acetone was discarded and replaced with fresh acetone solution 
and the solution was stored at -20°C overnight.  This process was repeated until 
cholesterol levels were below the detection threshold of a commercially available free 
cholesterol assay kit (Wako Chemicals, Richmond, VA, USA).  The recovered amount of 
phospholipid was determined by phosphorus assay as described later, the sample was re-
suspended in chloroform to make a final concentration of 5 mg/mL phospholipid (PL). 
 This material was utilized to create samples containing either 0, 5, 10 or 20% cholesterol 
wt/wt PL.  Cholesterol was obtained from Sigma (St. Louis, MO) and received as a 
powder. These samples were dried-down and re-suspended in 0.5 mL of buffer (140 mM 
NaCl, 10 mM Hepes, and 2.5 mM CaCl2, pH = 6.9) at a final PL concentration of 10 
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mg/mL. In addition, 4 similar samples were reconstituted with 5% SP-A wt/wt PL. The 
samples were analyzed for their biophysical function on the CBS as described below.     
 
2.2.3 Assessment of Surface Tension  
 The surface activity of the LA surfactant samples described above was assessed using a 
computer-controlled CBS (Schurch, 1989).  The chamber of the CBS was filled with a 
buffer solution (140 mM NaCl, 10 mM Hepes, and 2.5 mM CaCl2, pH = 6.9) containing 
10% sucrose (by mass) to increase the buffer density above that of surfactant 
(Gunasekara et al., 2005). A small bubble (0.035-0.045mL) was introduced into the 
chamber and allowed to float up and rest against the concave agarose plug at the top of 
the chamber. Approximately 0.1-0.15 L of LA sample was deposited just below the air-
liquid interface by a transparent capillary attached to a micromanipulator used for the 
precise approach of the capillary to the bubble. The bubble was imaged using a video 
camera (Pulnix TM-7CN, S/N: 017505) and recorded for future analysis. Throughout the 
experiment the chamber was kept at 37°C. Upon injection of surfactant, a 300s 
adsorption period was allowed, during which time there was no manipulation of the 
bubble and the change in the shape of the bubble was monitored. The chamber was then 
sealed and the bubble was rapidly expanded to a volume of 0.13 mL over a 1 second 
interval. Following this 5 minute period,  quasi-static cycling was performed by 
compressing and then expanding the bubble in a stepwise manner in increments of 20 % 
of the total volume in order to set the minimum (0.0090 mL) and maximum bubble 
volume (0.13mL) for subsequent assessment. Dynamic cycling, in which the bubble 
volume was smoothly changed to the defined volumes for 20 cycles at a rate of 20 
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cycles/min, was then performed to determine the minimum achievable surface tension 
during compression (minimum surface tension). The surface tensions of the bubbles were 
calculated based on the shape of the bubble at various stages throughout the CBS 
technique. Briefly, during initial adsorption images at precisely 0, 1, 5, 10, 30 and 300 
seconds were analyzed for surface tension. During dynamic cycling, every fifth image 
was analyzed, and the lowest minimum surface tension that was achieved for cycles 1, 2, 
5 and 10 were determined. 
 
2.2.4 Exogenous bovine lipid extract (BLES) surfactant cholesterol 
and SP-A reconstitution 
BLES was generously gifted by BLES Biochemicals (London, ON, CA).  BLES was 
extracted using chloroform and stored at -20°C until use.  Cholesterol was obtained from 
Sigma (St. Louis, MO) and received as a powder.  Cholesterol was dissolved in 
chloroform and reconstituted into BLES up to 5 or 20% w/w PL.  This solution was shell-
dried with gas and re-suspended with saline to a concentration of 15 mg/mL PL.  Five 
percent (w/w PL) human SP-A or an equal volume of saline was added to samples to 
create surfactant with 5% cholesterol ± SP-A and 20% cholesterol ± SP-A.  
Subsequently, 1.5 mM CaCl2 was added to all samples and saline was added to make a 
final concentration of 10 mg PL/mL.     
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2.2.5 Surgical procedure 
All procedures were approved by the animal use subcommittee at the University of 
Western Ontario in agreement with the guidelines of the Canadian Council of Animal 
Care. Animals were acclimatized for three days and had free access to water and a 
standard laboratory diet.  The surgical procedure for this experiment was similar to the 
methodology utilized by Maruscak and colleagues (2008) and Vockeroth and colleagues 
(2010).  Animal were subsequently anesthetized via intraperitoneal injection of 75 
mg/mL ketamine and 5 mg/mL xylazine in sterile 0.15 M NaCl.  Once a toe-pinch could 
not be observed, animals were given a subcutaneous injection of an analgesic (0.1 mg/kg 
buprenorphine) and a 0.2 mL subcutaneous injection of a topical anesthetic (sensorcaine 
0.5%)  at the site of incision.  The left and right jugular veins and the right carotid artery 
were exposed and catheterized with PE-50 tubing.  The left jugular catheter was used to 
deliver anesthetic/analgesic (0.5 – 2.5 mg/100g/h propofol) and the right jugular catheter 
was used to deliver fluid (sterile NaCl with 100 IU heparin/L) continuously (0.5 – 1.0 
mg/100g/h).  The carotid artery catheter was used to measure blood pressure and heart 
rate, collect blood for blood gas measurements (ABL 500 Radiometer, Copenhagen, DK) 
and deliver fluids (sterile NaCl with 100 IU heparin/L) continuously (0.5 – 1.0 
mg/100g/h).  Fluids and anesthetic/analgesic were delivered via infusion pumps (Harvard 
Apparatus Inc, South Nantucket Massachusetts). Subsequently, the trachea was exposed 
and a 14 gauge endotracheal tube was inserted and secured with 3-0 silk. 
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2.2.6 Mechanical ventilation procedure 
Following surgical preparation, animals were given a 0.1 mL bolus of a neuromuscular 
inhibitor (2 mg/mL pancurium bromide) and immediately connected to a volume-cycled 
rodent ventilator (Harvard Instruments, St. Laurent, PQ, CA) set to deliver 8 mL/kg tidal 
volume (Vt), respiratory rate (RR) of 54-58 breaths per minute (bpm), 5 cmH2O positive 
end-expiratory pressure (PEEP) and a fraction of inspired oxygen (FiO2) of 1.0.  Animals 
were ventilated for fifteen minutes prior to measuring initial baseline blood-gas 
measurements.  The inclusion criteria for all experiments were a blood gas measurement 
of PaO2 ≥ 400 mmHg.    
 
To deplete endogenous surfactant from the animals, a procedure as similarly used by 
Bailey and colleagues (2006) and Keating and colleagues (2007) was used.  Briefly, rats 
meeting the inclusion criteria were disconnected from the ventilator and given one total-
lung lavage of 10 mL 0.15 N NaCl via syringe attached to the endotracheal tube.  The 
peak inspiratory pressure (PIP) pre/post lavage and lavage volume 
administered/recovered were recorded.  After withdrawal of the lavage, the animal was 
re-attached to the ventilator.  The expiratory line was occluded for one breath to inflate 
the lungs and recruit any collapsed regions.  This process was repeated three additional 
times with 8 minutes between each lavage.  Following the fourth lavage, a blood gas 
measurement was taken to determine the animal had a PaO2 ≤ 150 mmHg.  Animals 
failing to meet the criteria were treated with further lavages ranging in volumes from 2-5 
mL until PaO2 ≤ 150 mmHg up to a maximum of eight total lavages.  Rats meeting the 
inclusion criteria were then randomized to receive either a 1 mL/kg BW of bolus of air or 
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a 1 mL/kg BW volume of surfactant (10 mg PL/mL) with 5% cholesterol (n=6), 5% 
cholesterol + SP-A (n=7), 20% cholesterol (n=6) or 20% cholesterol + SP-A (n=6) 
intratracheally.  Rats were then placed back on ventilation, given one breath hold and 
ventilated for 120 minutes.  Airway pressure, hemodynamics, and blood gas 
measurements were recorded every 15 minutes.   
 
2.2.7 Rat surfactant lavage collection and processing 
Rats were administered 75 mg/kg BW sodium pentobarbital via the left jugular catheter 
to lower blood pressure.  Animals were exsanguinated by severing the descending aorta. 
 A midline sternectomy was performed to open the chest cavity.  After, lungs were 
treated to a whole-lung lavage using five 10 mL aliquots of 0.15 M saline; each aliquot 
was instilled and removed three times (Veldhuizen et al., 2002). 
 
Collected lavage samples were centrifuged at 150 g for 10 mins.  Five mL of supernatant 
from the lavage containing the surfactant sub-fraction (TS) was aliquoted in 1 mL 
volumes and stored at -20°C.  The remaining surfactant was centrifuged at 40 000g for 15 
minutes to separate the supernatant containing the small aggregate (SA) sub-fraction 
(Yamada et al., 1990) and the pellet containing the large aggregate (LA) was re-
suspended in 2 mL of 0.15 M NaCl saline.  The SA and LA sub-fractions were stored 
with the TS sub-fraction at -20°C. 
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2.2.8 Surfactant analysis  
A modified Duck-Chong phosphorous assay was performed on each total surfactant, LA 
and SA sample to determine the phospholipid content in each (Duck-Chong, 1979).  
Briefly, aliquots of total surfactant, LA and SA samples were added to a solution 
containing 1 mL ddH2O, 1 mL methanol and 2 mL chloroform.  This mixture was then 
centrifuged at 150 g for 10 mins to separate the aqueous and organic solvent layers.  The 
organic solvent layer was extracted and dried-down via exposure to O2 gas in a 37°C 
water bath until the liquid chloroform had evaporated.  The remaining solute was ashed 
on a hot-plate after which 1 mL of 1 N HCl was added.  Then, the samples were then 
placed into a heating block at 100°C for 15 mins.  Malachite green dye was added to all 
surfactant samples and the resulting colour was analyzed on a plate reader.    
 
2.2.9 Statistical Analysis 
Statistical analysis of cholesterol and SP-A reconstituted human proteinosis surfactant 
was performed using a two-way repeated measures analysis of variance (ANOVA) with a 
Tukey’s post-hoc test.   Analysis of surface area reduction for human proteinosis 
surfactant during compression was done by t-test.  Results from our study using rats 
treated with BLES elevated to 5 and 20% cholesterol with and without SP-A were 
analyzed with a two-way ANOVA followed by Tukey’s post-hoc test.  Means are 
reported ± SEM.  Values were considered significantly different at a probability value < 
0.05. 
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2.3 Results 
 
2.3.1 In vitro experiment 
2.3.1.1 Adsorption  
We tested the surface tension at the air-liquid interface within the CBS of human 
surfactant reconstituted with different levels of cholesterol with and without SP-A by 
allowing the surfactant to adsorb to the air-liquid interface over the course of 300 s.  First, 
figure 2.1A shows the effect of increasing concentrations of cholesterol, without SP-A, 
on the surface tension following adsorption of human surfactant. Surfactant with 0% 
cholesterol demonstrated rapid adsorption reaching equilibrium surface tension of 
approximately 23mN/m in 30 seconds.  Human surfactant containing 5% cholesterol had 
adsorption values that were not significantly different from the 0% cholesterol samples at 
any time during adsorption except for the 5 second time-point. At this time, the 5% 
cholesterol samples had significantly higher surface tension values compared to the 0% 
cholesterol sample.  Samples with 10 and 20% cholesterol had slower adsorption 
compared to the 0 and 5% cholesterol sample. This difference was statistically significant 
from 5 to 60 seconds for 10% cholesterol, and from 5 to 30 seconds for 20% cholesterol, 
as compared to the 0% cholesterol sample.  
 
The surface tension during 300 s of adsorption at the air liquid interface for human 
proteinosis surfactant samples reconstituted with various levels of cholesterol and SP-A 
is shown in figure 2.1B.  Over the course of 300 s, there were no significant differences 
58 
 
amongst the surfactant samples reconstituted with different levels of cholesterol.  
Comparisons between surfactant containing similar levels of cholesterol but with or 
without SP-A showed that there were no significant differences in surface tension 
between surfactant containing 5% cholesterol regardless of the presence of SP-A.  
However, it was observed that surfactant containing 10% cholesterol + SP-A had 
significantly reduced surface tension from 0 – 60 s as compared to surfactant with 10% 
cholesterol without SP-A.  Similarly, surfactant containing 20% cholesterol with SP-A 
showed significantly lower surface tension from time points 10 – 60 s as compared to 
surfactant containing 20% cholesterol without SP-A. 
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Figure 2.1 Surface tension (mN/m) during 300 s of initial adsorption of human surfactant 
reconstituted with different levels of cholesterol without (A) and with (B) SP-A, as 
indicated in the legend.  Values are reported as mean ± standard error, a = p <0. 05 versus 
0% cholesterol, b = p<0.05 vs. 5% cholesterol, #= p <0.05 versus 10% cholesterol 
without SP-A, *= p<0.05 vs. 20% cholesterol without SP-A, n = 3/group. 
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2.3.1.2 Minimum achievable surface tension 
The minimum achievable surface tension of human proteinosis surfactant reconstituted 
with various levels of cholesterol over the course of ten dynamic expansion-compression 
cycles is shown in figure 2.2A.  Within each surfactant group, there were no significant 
differences in minimum surface tension throughout all expansion-compression cycles.  
Comparison between the surfactant samples with 0% cholesterol and 5% cholesterol 
revealed only a significantly higher surface tension during 10
th
 dynamic expansion-
compression cycle in the 5% cholesterol group as compared to the 0% cholesterol group.  
In contrast, samples with 10% cholesterol and 20% cholesterol had significantly higher 
surface tensions than the 0% cholesterol and 5% cholesterol groups throughout all cycles.  
Additionally, only during cycle #1 did samples containing 20% cholesterol have a 
significantly higher minimum surface tension than samples containing 10% cholesterol.   
 
The minimum achievable surface tension of human surfactant with various levels of 
cholesterol and SP-A during expansion-compression cycles 1, 2, 5 and 10 is shown in 
figure 2.2B.  No significant differences in minimum surface tension within each 
surfactant group were found throughout all expansion-compression cycles.  Amongst 
surfactant groups reconstituted with different levels of cholesterol with added SP-A, there 
were no significant differences in minimum surface tension between groups with 0, 5 or 
10% cholesterol throughout all expansion-compression cycles.  However, surfactant 
containing 20% cholesterol + SP-A had significantly higher minimum surface tension 
than all other surfactant groups reconstituted with SP-A.  Additionally, there were 
significant differences between groups treated with SP-A and those without.  
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Specifically, surfactant with 5% cholesterol + SP-A had a significantly lower minimum 
surface tension at the end of cycle 10 as compared to surfactant with 5% cholesterol 
without SP-A.  Similarly, surfactant with 10 and 20% cholesterol + SP-A had 
significantly lower minimum surface tensions when compared to similar treatments 
lacking SP-A throughout all expansion-compression cycles.   
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Figure 2.2 Minimum surface tension (mN/m) of human surfactant reconstituted with 
different levels of cholesterol without (A) and with (B) SP-A during various dynamic 
compression-expansion cycles.  Values are reported as mean ± standard error, a = p <0.05 
vs. 0% cholesterol, b = p<0.05 vs. 5% cholesterol, c = p <0.05 vs. 10% cholesterol and 
*= p<0.05 versus same sample without SP-A, n = 3/group. 
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Table 2.1 shows the relative changes in surface area needed to attain minimum surface 
tension values in samples containing 0 or 20% cholesterol with or without SP-A in order 
to represent the extreme minimum and maximum cholesterol concentrations in our study.  
Firstly, there were no differences in the minimum surface tension or relative changes in 
surface area within each surfactant group between the first and tenth expansion-
compression cycle.  Secondly, the minimum surface tension achieved in surfactant with 
0% cholesterol ± SP-A was lower than the surfactant with 20% cholesterol ± SP-A.  
However, the % relative area required to attain these values was different between the 0% 
cholesterol ± SP-A and 20% cholesterol + SP-A.  Lastly, surfactant treated with 20% 
cholesterol alone had increased minimum surface tension and decreased relative surface 
area than all other samples in compression-expansion cycles 1 and 10.  
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Table 2.1 Relative surface area (%) required to attain minimum achievable surface 
tension (mN/m) of human surfactant reconstituted with 0 or 20% cholesterol with and 
without the addition of SP-A; n = 1/group. 
 Expansion-compression cycle #1 Expansion-compression cycle #10 
 Surface tension 
(mN/m) 
% relative 
area 
Surface tension 
(mN/m) 
% relative area 
0% cholesterol 
 
1.13 
 
51.81 
 
0.91 57.67 
0% cholesterol + 
SP-A 
1.95 44.45 
 
2.14 46.56 
20% cholesterol 
 
15.70 
 
18.53 
 
15.60 
 
18.45 
 
20% cholesterol + 
SP-A 
10.62 
 
49.69 
 
8.98 
 
47.84 
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2.3.2 In vivo experiment 
2.3.2.1 Arterial oxygenation 
Surfactant depleted rats were treated with exogenous surfactant of various compositions 
in order to determine the physiological effects of excess cholesterol and SP-A in 
surfactant.   Arterial oxygenation was measured to determine lung function over the 
course of 120 minutes of MV at 15 minute intervals.  Firstly, Figure 2.3 shows that the 
oxygenation of animals receiving 5% cholesterol was significantly increased 15 mins 
after the last sequential lavage measurement was recorded and remained significantly 
higher throughout ventilation.  Additionally, rats administered surfactant containing 5% 
cholesterol had significantly higher oxygenation throughout ventilation as compared to 
rats treated with an air bolus alone.  Rats administered surfactant containing 20% 
cholesterol did have an increase in oxygenation after their last sequential lavage and they 
had similar oxygenation to animals treated with an air bolus alone throughout ventilation.   
 
We also tested the effects of SP-A on the oxygenation of rats administered surfactant 
containing 5 or 20% cholesterol.  Figure 2.3 shows that rats administered surfactant 
containing 5% cholesterol + SP-A had significantly increased oxygenation after the last 
sequential lavage and significantly higher oxygenation throughout ventilation as 
compared to rats treated with an air bolus alone.  Similarly, rats administered surfactant 
reconstituted with 20% cholesterol + SP-A had significantly higher oxygenation after 
their last sequential lavage and also had significantly higher oxygenation than air treated 
rats from time points 15 – 75.  
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Figure 2.3 Arterial oxygenation content (mmHg) after endogenous surfactant depletion 
and administration of BLES with various amounts of cholesterol ± SP-A and 120 minutes 
of mechanical ventilation.    Values are means ± SE, n = 6-7/group, a p<0.05 vs. 5% 
cholesterol, b p<0.05 vs. 5% cholesterol + SP-A, c p<0.05 vs. 20% cholesterol + SP-A. 
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2.3.3 Surfactant analysis 
After 120 minutes of MV, rats were sacrificed and were given a whole lung lavage to 
recover surfactant.  Analysis of collected surfactant from lavage after exogenous 
surfactant administration and mechanical ventilation showed that within the total 
surfactant (2.4A), LA (2.4B) or SA (2.4C) sub-fractions of surfactant, there were no 
significant differences amongst treatment groups regardless of cholesterol or SP-A 
content. 
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Figure 2.4 Surfactant pool sizes (mg PL/kg BW) between rats depleted of endogenous 
surfactant administration of BLES with various amounts of cholesterol ± SP-A and 120 
minutes of mechanical ventilation.  Measurement of (A) total surfactant (B) large and (C) 
small aggregate pool sizes. Values are means ± SE, n = 6-7/group. 
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2.4 Discussion 
 
The hypothesis for this study was that elevated cholesterol in surfactant impairs the 
biophysical properties of the material contributing to decreased lung function, but the 
presence of SP-A could mitigate these effects. To test this hypothesis we performed in 
vitro and in vivo experiments, both of which provided results that indicated that elevated 
cholesterol was detrimental and that SP-A could mitigate the effect. For the in vitro 
studies outcomes were biophysical in nature, whereas our in vitro experiments 
determined the effects of high cholesterol in surfactant on physiology. Together, these 
observations support the conclusion that elevated cholesterol in surfactant inhibits the 
biophysical properties of the material which contributes to lung dysfunction, but SP-A 
can mitigate these effects and improve physiology. 
  
The first part of our hypothesis examined whether elevated surfactant cholesterol levels 
would affect the biophysical properties of the material and whether impairments would 
lead to physiological dysfunction.  To investigate this, we tested the biophysical 
properties of surfactant reconstituted with various levels of cholesterol on the CBS.  In a 
subsequent experiment, we administered surfactant containing 5 or 20% cholesterol to 
ventilated and surfactant depleted rats.  Based on these two experiments, we determined 
that high cholesterol in surfactant impairs the surface tension reducing capability of the 
material by observing that surfactant containing 10 and 20% cholesterol had high surface 
tensions after adsorption and higher minimum achievable surface tensions during 
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compression.  The dysfunction results in impaired oxygenation in rats treated with 
surfactant containing 20% cholesterol.  Previous studies have investigated the 
physiological effects of surfactant reconstituted with cholesterol (Keating et al., 2007); 
however, ours is the first to show that cholesterol-mediated surfactant dysfunction results 
in decreased oxygenation.  These findings suggests that biophysical impairment due to 
high cholesterol in surfactant contributes to dysfunctional lung function and may 
propagate the development of lung injury.  
 
The second part of our hypothesis was to investigate whether SP-A can mitigate the 
effects of cholesterol-mediated surfactant dysfunction.  Previous in vitro studies have 
determined that reconstitution of SP-A to surfactant inhibited by serum-proteins can 
mitigate surfactant dysfunction (Cockshutt et al., 1990).  Despite this knowledge of SP-
A’s ability to mitigate this particular form of surfactant inhibition, it was unknown 
whether it would also be able to restore surfactant function when the material is inhibited 
by high cholesterol.  To determine the effects of SP-A on surfactant inhibited by high 
cholesterol, we performed two different experiments.  Our in vitro study utilized 
surfactant reconstituted with various concentrations of cholesterol with or without 5% 
SP-A and examined their biophysical properties on the CBS.   Our in vivo experiment 
utilized ventilated and surfactant depleted rats and administered exogenous surfactant 
containing 5 or 20% cholesterol with and without SP-A.  These two experiments revealed 
two important observations regarding SP-A and cholesterol mediated surfactant 
dysfunction.  First, the addition of SP-A improved the biophysical properties of surfactant 
with high cholesterol by reducing the surface tension after adsorption and minimum 
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achievable surface tension.  Secondly, the presence of SP-A significantly increased the 
oxygenation in rats treated with surfactant containing 20% cholesterol when compared to 
baseline (BL) and air treated animals.  These observations indicate that SP-A can mitigate 
cholesterol-mediated surfactant dysfunction which results in significant improvement of 
the lung’s ability to facilitate oxygenation.   
 
While previous studies have shown that SP-A has an important role to enhance the 
biophysical properties of surfactant, it has also been shown that SP-A, under 
physiologically normal conditions, is not necessary for lung function (Korfhagen et al., 
1996).  Specifically, a study conducted by  Korfhagen and colleagues (1996) used SP-A 
null mice and showed that their lung compliance, physiology and surfactant function in 
vitro was not affected as compared to wild-type mice.  However, mice lacking SP-A had 
increased minimum surface tensions when phospholipid concentrations were decreased.  
This finding indicates that SP-A has an important role in maintaining surfactant function 
when the system is otherwise compromised.  This notion is further supported by work 
showing that SP-A can mitigate protein-mediated surfactant dysfunction (Cockshutt et 
al., 1990); oxidized lipid-mediated inhibition (Capote et al., 2003; Bailey et al., 2006) 
and, as our observations now indicate, cholesterol-mediated dysfunction.  Based on these 
aforementioned studies, while SP-A enhances the biophysical properties of surfactant, 
SP-A is not wholly necessary for proper lung function under normal and healthy 
conditions (Korfhagen et al., 1996).  However, SP-A has an important role in maintaining 
lung and surfactant function when surfactant’s biophysical properties are compromised 
by a variety of inhibitory mediators.     
72 
 
 
The mechanism(s) of cholesterol-mediated surfactant inhibition has been studied, but the 
observations are open to various, sometimes conflicting, interpretations.  For instance, the 
effect of cholesterol on the biophysical function of surfactant films can vary based on the 
lipid profile of the film examined.  For example, several studies have shown that 
surfactant films composed of purely DPPC are rendered dysfunctional when 
physiological amounts of cholesterol are present (Suzuki et al., 1982; Yu & Possmayer, 
1998; Yu et al., 1999).  In contrast, surfactant films composed of mixed-lipids are not 
impaired by physiological amounts of cholesterol, but tend to show dysfunction when 
cholesterol levels are increased (Gunesakara et al., 2005).  In general, studies attempting 
to reconcile the effects of cholesterol on surfactant’s biophysical properties suggest that 
elevated cholesterol affects the fluidity of the lipid film by affecting the organization of 
surfactant lipids (Keating et al., 2007).  Additionally, Panda and colleagues (2004) 
observed an inability to form organized lipid domains in surfactants with high 
cholesterol.  These lipid structures are not present in dysfunctional surfactant and are 
thought to be necessary for proper surfactant function.  Based on these observations, it is 
suggested that high cholesterol modifies the lipid organization of surfactant and these 
changes to the organization of surfactant films are thought to be the principle mechanism 
of cholesterol-mediated inhibition.  Although we have shown that SP-A is able to 
mitigate the inhibitory effects of high cholesterol on surfactant function, it is currently 
unclear how SP-A is able to facilitate this.  One theory is SP-A is able to act in 
conjunction with SP-B to enhance the adsorption properties of surfactant which 
corresponds to improved biophysical function (Venkitaraman et al., 1990).  Further 
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research should be conducted to elucidate the molecular mechanism behind SP-A’s 
ability to mitigate cholesterol-mediated inhibition.    
 
Although not the main focus of this study, we also examined the surfactant subfractions 
from our ventilated and surfactant depleted rats.  This experiment was done in order to 
better understand the effects of elevated cholesterol and exogenous SP-A on surfactant 
metabolism in an in vivo setting.  Previous in vivo experiments regarding SP-A and 
surfactant metabolism have shown that SP-A promotes the re-uptake of surfactant into 
type-2 cells (Wright & Dobbs, 1991) and may modulate the secretion of surfactant as 
well (Rice, 1987; Wright & Dobbs, 1991).  However, these experiments used 
concentrations of SP-A that were higher than what would be present physiologically.  
Based on the surfactant we recovered, it was observed that there were no significant 
differences in the amounts of total surfactant, SA or LA sub fractions recovered between 
animals treated with 5 and 20% cholesterol.  However, we observed a trend of lower 
recovered surfactant pool sizes from animals treated with surfactant reconstituted with 
SP-A as compared to animals treated with surfactant lacking the protein.  Thus, our 
observations suggest that while elevated cholesterol does not affect surfactant 
metabolism, SP-A may have a regulatory role on surfactant metabolism within the lungs.  
Lastly, it is important to mention that our in vitro determination of surfactant inhibition 
due to high cholesterol was performed on surfactant obtained from a human patient.  
Although surfactant composition is highly conserved amongst homeothermic mammals 
(Veldhuizen et al., 1998), to our knowledge this is the first study to examine the role of 
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excess cholesterol on human surfactant and, importantly, implicate it as a potential 
contributor to the development of lung injury in human patients.  
 
2.5 Conclusion 
 
In conclusion, this study demonstrated that elevated levels of cholesterol in surfactant 
impairs the material’s ability to decrease and this has physiological consequences in 
terms of arterial oxygenation levels in ventilated rats.  However, the presence of SP-A 
can improve the surface tension reducing capability of surfactant with cholesterol 
mediated impairment which also improves oxygenation in vivo.   
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Chapter 3  
3 The effect of diet-induced serum hypercholesterolemia 
on the development of lung injury  
 
3.1 Introduction 
 
Acute Respiratory Distress Syndrome (ARDS) is a severe pulmonary disorder caused by 
both direct, such as acid aspiration and indirect insults to the lungs, such as systemic 
bacterial infection (Ware & Matthay, 2000).  Clinically, ARDS can range from a “mild” 
form which is defined as having arterial oxygenation between 200 mmHg < PaO2/FiO2 ≤ 
300 mmHg to “severe” ARDS with PaO2/FiO2 ≤ 100 mmHg (Rubenfeld et al., 2012).  
Currently, patients afflicted with ARDS require the use of mechanical ventilation (MV) 
as a supportive measure (Lee & Slutsky, 2001); however, MV also carries a risk of 
causing further pulmonary damage (Webb & Tierney, 1974; Dreyfuss & Saumon, 1998; 
Brower et al., 2000; Veldhuizen et al., 2001).  Overall, patients with ARDS have a 30% 
mortality rate with no known curative therapy (Brower et al., 2000).  This high risk of 
mortality due to ARDS emphasizes the need to better understand the pathophysiology of 
the disorder.   
 
Although ARDS can arise from both direct and indirect insults to the lungs, one common 
feature among patients with the condition is impairment to their pulmonary surfactant 
(Gregory et al., 1991; Veldhuizen et al., 1995; Gunther et al., 1996).  Pulmonary 
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surfactant is a lipoprotein complex found at the air-liquid interface of alveoli (Possmayer 
et al., 1984; Goerke, 1998; Possmayer, 2004).  It is produced by type-two alveolar cells 
which release surfactant in the form of what are called large aggregates (LA) into the 
hypophase within alveoli where it can form a surface-active film.  This surface active 
film decreases the effort required to breathe and prevents alveolar collapse at low lung 
volumes (Possmayer, 2004).  Changes to the alveolar surface area during respiration 
causes LA to convert into a non-surface active component (small aggregates, SA) (Gross, 
1995; Lewis et al., 1990).  The SA are then taken-up by type-two cells and can be 
recycled into large aggregates (Wright, 1991)
 
or processed for degradation (Wright, 
19901.  Surfactant is composed mainly of phospholipids (80-90%) but also contains 
neutral lipids, such as cholesterol (3-10%), and surfactant associated proteins (5-10%) 
(Veldhuizen et al., 1998; Possmayer, 2004).  The precise balance of surfactant’s 
constituent components is paramount to the material’s biophysical properties and changes 
to the composition can impair surfactant’s ability to function. 
 
In the context of ARDS, changes to surfactant’s composition and function have been 
shown to be associated with this condition.  Numerous studies have demonstrated 
alterations to the surfactant phospholipid composition (Gunther et al., 1996; Schmidt et 
al., 2001), changes to the surfactant proteins levels (Gregory et al., 1991; Gunther et al., 
1996; Schmidt et al., 2007) and decreased levels of the LA form of surfactant 
(Veldhuizen et al., 1995; Gunther et al., 1996). These changes, together with inhibition 
by serum proteins that have leaked into the lung (Cockshutt, 1991), have traditionally 
thought to be the main contributors to surfactant dysfunction. Interestingly, recent in vitro 
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studies and experiments with animal models of lung injury have demonstrated that an 
excess cholesterol within surfactant also represent an important mechanism by which 
surfactant becomes dysfunctional (Davidson et al.,  2000; Panda et al., 2004; Gunasekara 
et al., 2005; Vockeroth et al.,  2010). For example, an experiment using an in vivo rat 
model of ventilator induced lung injury (VILI) showed that removing cholesterol from 
the surfactant obtained from injured animals restored its ability to reduce surface tension 
(Vockeroth et al., 2010). Since the majority of surfactant cholesterol originates from the 
serum with only 1% of surfactant cholesterol endogenously produced within the lungs 
(Guthmann et al., 1997; Orgeig & Daniels, 2001) this observation of cholesterol-
mediated inhibition has raised the question whether serum hypercholesterolemia 
increases one’s susceptibility towards developing more severe lung injury  
 
Therefore, to investigate the role of serum cholesterol in lung injury and surfactant, we 
used a model of diet-induced hypercholesterolemia in male Wistar rats and randomized 
them into three distinct injury models: a ventilator-induced lung injury (VILI) model, an 
acid-aspirated lung injury model and a surfactant depleted lung injury model.    In all of 
these models, outcomes that were assessed were physiological measurements and 
surfactant analysis.  We hypothesized that serum hypercholesterolemia will predispose 
the rats to developing severe lung injury due to changes to their pulmonary surfactant 
system. 
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3.2 Methods 
 
3.2.1 Animals  
Eighty-six six-week old male Wistar rats (Charles River, St. Constant, PQ, CA) were 
used for this experiment. All procedures were approved by the animal use subcommittee 
at the University of Western Ontario in agreement with the guidelines of the Canadian 
Council of Animal Care. Animals were acclimatized for three days and had free access to 
water and a standard laboratory diet.  Following this period, animals were randomized 
into either a standard laboratory diet (“standard diet”) or a high cholesterol diet (“high 
cholesterol diet”: 0.5% cholic acid and 1.25% cholesterol by mass; Harlan Teklad,  
Madison, WI, USA ).  Rats were fed their respective diet for 17 – 20 days.  
 
3.2.2 Surgical procedure 
All animals included in each of the 3 experimental models that underwent MV all 
underwent the same initial surgical procedure. This surgical procedure was similar to 
those used by Maruscak and colleagues (2008) and Vockeroth and colleagues (2010).  
Animals were anesthetized via intraperitoneal injection of 75 mg/mL ketamine and 5 
mg/mL xylazine in sterile 0.15 M NaCl.  Once a reaction from a toe-pinch could not be 
observed, animals were given a subcutaneous injection of an analgesic (0.1 mg/kg 
buprenorphine) and a 0.2 mL subcutaneous injection of a topical anesthetic (sensorcaine 
0.5%) at the site of incision.  The left and right jugular veins and the right carotid artery 
were exposed and catheterized with PE-50 tubing.  The left jugular catheter was used to 
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deliver anesthetic/analgesic (0.5 – 2.5 mg/100g/h propofol) and the right jugular catheter 
was used to deliver fluid (sterile NaCl with 100 IU heparin/L) continuously (0.5 – 1.0 
mg/100g/h).  The carotid artery catheter was used to measure blood pressure and heart 
rate, collect blood for blood gas measurements (ABL 500 Radiometer, Copenhagen, DK) 
and deliver fluids (sterile NaCl with 100 IU heparin/L) continuously (0.5 – 1.0 
mg/100g/h).  Fluids and anesthetic/analgesic were delivered via infusion pumps (Harvard 
Apparatus, Model 22). Subsequently, the trachea was exposed and a 14 gauge 
endotracheal tube was inserted and secured with 3-0 silk. 
 
Following surgical preparation, animals were given a 0.1 mL bolus of a neuromuscular 
inhibitor (2 mg/mL pancuronium bromide) and immediately connected to a volume-
cycled rodent ventilator (Harvard Instruments, St. Laurent, PQ, CA) set to deliver 8 
mL/kg tidal volume (Vt), respiratory rate (RR) of 54-58 breaths per minute (bpm), 5 
cmH2O positive end-expiratory pressure (PEEP) and a fraction of inspired oxygen (FiO2) 
of 1.0.  Animals were ventilated for fifteen minutes prior to measuring initial baseline 
blood-gas measurements.  The baseline (BL) inclusion criteria following this procedure 
was a blood gas measurement while breathing 100% oxygen of PaO2/FiO2 ≥ 400 mmHg.  
 
3.2.3 High tidal volume mechanical ventilation model of lung injury 
In this experiment standard diet and high cholesterol diet animals each were randomized 
to 3 experimental groups: non-vent, low-stretch and high-stretcth mechanical ventilation 
for 120 mins.  The ventilator procedure used in this part of the study was based on the 
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procedure used by Maruscak and colleagues (2008).  Animals randomized to no 
mechanical ventilation (“Non-vent”, n = 5-6/group) were sacrificed via sodium 
pentobarbital overdose delivered via intraperitoneal injection. A total of 9 – 10 mL 
aliquot of blood was collected via the descending aorta.  Of this, 3.5 mL was collected in 
a 6 mL Lithium Heparin Vacutainer tube (BD, Franklin Lakes, NJ, USA) for total serum 
cholesterol, triglyceride and HDL analysis.  5.5 – 6.5 mL of blood was collected in a 10 
mL syringe with 0.1 mL of heparin (1000 USP/mL) for further serum analysis.  Animals 
were then exsanguinated by severing the descending aorta.  A midline sternectomy was 
performed to expose the chest cavity and a pressure-volume curve was determined and 
animals were treated to a whole-lung lavage as described below.        
 
Animals randomized to one of the ventilation strategies underwent the surgical procedure 
described above followed by either continued ventilation with “low stretch” (n = 6-7: Vt 
= 8 mL/kg, RR = 54-58 bmp, PEEP = 5 cmH2O, FiO2 = 1.0), or “high stretch” (n=4-6: Vt 
= 30 mL/kg, RR = 16 – 18 bmp, PEEP = 0 cmH2O, FiO2 = 1.0). Animals were detached 
from the initial ventilator for 10 seconds and re-attached to the either the ventilator with 
the low stretch or the high stretch settings to begin the 2 hours of ventilation.  Airway 
pressure, hemodynamics, and blood gas measurements were monitored every 15 minutes. 
 
In a separate experiment, animals fed a standard or high cholesterol diet were ventilated 
with high-stretch ventilation for 180 minutes to ascertain whether the effects of diet 
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induced serum hypercholesterolemia on lung function would be further exacerbated over 
time.   
 
3.2.4 Blood collection and lavage collection. 
After 120 or 180 mins of ventilation, 3.5 mL of blood was collected from animals via the 
carotid artery catheter in a 6 mL Lithium Heparin Vacutainer tube (BD Biosciences, 
Franklin Lakes, NJ, USA) for serum cholesterol analysis.  Following, animals were 
euthanized with an overdose of sodium pentobarbital (110 mg/kg) via the left jugular 
catheter to lower blood pressure.  Animals were then exsanguinated by severing the 
descending aorta and a midline sternectomy was performed to open the chest cavity.  
After, lungs were washed with a whole-lung lavage using five 10 mL aliquots of 0.15 M 
saline.  Each aliquot was instilled and removed three times and the total volume of the 
five aliquots was recorded (Veldhuizen et al., 2002). The lavage material was 
subsequently processed as described below. 
 
3.2.5 Acid induced lung injury model 
The second model of injury was a model of acid aspiration injury. For this part of the 
study, a similar methodology as described by Folkesson and colleagues (1995) was used 
to generate an acid-induced lung injury model.  Following the surgical procedure 
described above, rats meeting the inclusion criteria were randomized to receive either 1M 
HCl (1 mL/kg) or air (1 mL/kg).  The rats were disconnected from ventilation and placed 
on their right side.  Half of the treatment volume was administered intratracheally via 
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pipette after which the animal was reconnected to the ventilator and given two breath 
holds.  The animal was then placed in a supine position for five breaths after which the 
animal was disconnected from the ventilator and the procedure was repeated on its left 
side.  Rats were then ventilated with Vt = 8 mL/kg, RR = 54-58 bmp, PEEP = 5 cmH2O 
and FiO2 = 1.0 for 120 minutes with airway pressure, hemodynamics, and blood gas 
measurements monitored and recorded every 15 minutes. Animals were euthanized and 
lavaged as described above. 
 
3.2.6 Surfactant depletion model  
The third model involved surfactant depletion. Our methods were similar to described by 
Bailey and colleagues (2006) and Keating and colleagues (2007).  Animals meeting the 
inclusion criteria following the surgical procedure described above were disconnected 
from the ventilator subjected to a whole lung lavage using 10 mL 0.15 N NaCl via 
syringe attached to the endotracheal tube.  The peak inspiratory pressure (PIP) pre/post 
lavage and lavage volume administered/recovered were recorded.  After withdrawal of 
the lavage, the animal was re-attached to the ventilator and given a single breath hold.  
This process was repeated four times with 10 minutes between each lavage.  Following 
the fourth lavage, a blood gas measurement was taken to determine if the animal had met 
the second inclusion criteria of PaO2 ≤ 250 mmHg and PIP ≤ 16 cmH2O.  Animals failing 
to meet the criteria were treated with further lavages ranging in volumes from 2-5 mL up 
to a maximum of seven total lavages.  These repeated lavage samples were collected and 
analyzed for surfactant composition as described below.  Subsequently, animals were 
ventilated for 120 min, euthanized and lavaged as described above. 
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3.2.7 Serum total cholesterol analysis 
Blood samples collected in Lithium Heparin Vacuatiner tubes were analysed for total 
cholesterol levels via as performed by the University Hospital Core Lab (University 
Hospital, London, ON, CA).    
 
3.2.8 Surfactant processing and analysis 
Blood samples and post-ventilation and total lavage were centrifuged at 150 g for 10 
mins.  The resulting blood serum was extracted and stored at -80°C.  Five mL of 
supernatant from the lavage containing the surfactant was aliquoted in 1 mL volumes and 
stored at -20°C.  The remaining surfactant (TS) was centrifuged at 40 000g for 15 
minutes to separate the supernatant containing the small aggregate (SA)  (Yamada et al., 
1990) sub-fraction and the pellet containing the large aggregate (LA) (Veldhuizen et al., 
1993); the LA was re-suspended in 2 mL of 0.15 M NaCl saline.  Surfactant and 
surfactant sub-fraction samples were stored with the collected surfactant at -20°C. 
 
A modified Duck-Chong phosphorous assay was performed on each total surfactant, LA 
and SA sample to determine the phospholipid content in each (Duck-Chong, 1979).  
Briefly, aliquots of total surfactant, LA and SA samples were added to a solution 
containing 1 mL ddH2O, 1 mL methanol and 2 mL chloroform.  This mixture was then 
centrifuged at 150 g for 10 mins to separate the aqueous and organic solvent layers.  The 
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organic solvent layer was extracted and dried-down via exposure to O2 gas in a 37°C 
water bath until the liquid chloroform had evaporated.  The remaining solute was ashed 
on a hot-plate after which 1 mL of 1 N HCl was added.  Then, the samples were then 
placed into a heating block at 100°C for 15 mins.  Malachite green dye was added to all 
surfactant samples and the resulting colour was analyzed on a plate reader.    
 
Total protein in surfactant samples were measured via micro BCA protein assay 
according to the manufacturer’s instructions (Pierce Biotechnology, Rockford, IL, USA).  
Free cholesterol in LA samples was determined by a Free Cholesterol-E kit according to 
the manufacturer’s instructions (Wako Chemicals, Richmond, VA, USA).  
 
3.2.9 Statistical analysis 
Data are expressed as means ± standard error (SE).  Differences between groups 
measured over time was done by a two-way repeated measures analysis of variance 
(ANOVA) with Tukey’s post-hoc test.  A two-way student’s T-test was used to determine 
significance for comparisons between two groups and in the surfactant depletion study.  
For all other measures, a two-way ANOVA followed by Tukey’s post-hoc test was used.  
All statistics were performed using statistical analysis program GraphPad Prism 
(GraphPad Software, La Jolla, CA, USA).  Probability (p) values of less than 0.05 were 
considered statistically significant. 
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3.3 Results 
 
Figure 3.1 shows the concentration of total serum cholesterol in rats after 14-17 days on 
either the standard or high cholesterol diet.  Rats fed the high cholesterol diet had 
significantly higher total serum cholesterol compared to rats fed the standard diet 
(P<0.0001).  However, there were no significant differences between the weights of rats 
fed the standard or high cholesterol diet (369 ± 4 g vs. 366 ± 4 g, respectively).     
 
3.3.1 Experiment #1: High tidal volume mechanical ventilation 
model of lung injury 
Figure 3.2 shows the peak inspiratory pressure (PIP) of rats placed on either (A) low 
stretch or (B) high stretch MV.  The PIP of animals placed on low stretch MV did not 
show significant increases at any time point from BL through to the end of MV.  
Additionally, there were no significant differences of PIP at any time point during MV 
between animals fed a control or high cholesterol diet.  In contrast, rats placed on high-
stretch MV did have significantly increased PIP immediately after BL.  However, there 
were no significant differences in PIP of animals fed either the control or high cholesterol 
diet throughout the duration of MV.   
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Figure 3.1 Concentration of total serum cholesterol (mmol/L, n = 14 – 19/group) in rats 
fed either a standard or high cholesterol diet.    Values are means ± SE, *P<0.0001 vs. 
standard diet. 
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Figure 3.2 Peak inspiratory pressure (cmH2O) throughout 120 minutes of low stretch (A) 
or high stretch (B) ventilation.    Values are means ± SE, n = 5-7/group. 
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Figure 3.3 shows the arterial oxygenation (PaO2) of rats placed on the standard or high 
cholesterol diet and randomized to receive either (A) low stretch or (B) high stretch 
mechanical ventilation.  In rats ventilated with low-stretch ventilation, there were no 
significant differences between oxygenation values throughout ventilation as compared to 
BL values in either diet group.  Furthermore, there were no significant differences in 
oxygenation between rats fed a control diet or rats fed a high cholesterol diet at any time 
point during MV.  Similarly, rats placed on high-stretch MV did not show any significant 
changes in oxygenation after BL and there were no significant differences in oxygenation 
between rats fed a control diet or rats fed a high cholesterol diet (figure 3.3B).    
 
Surfactant (A), SA (B), LA (C) pools and percentage cholesterol within the large 
aggregate component of surfactant (D) are shown in figure 3.4.  There were significant 
increases in the amount of surfactant, SA and LA found within the lavage of animals 
placed on high-stretch MV as compared to non-ventilated animals and a significant 
increase in the amount of surfactant and SA in animals placed on high-stretch MV as 
compared to the low-stretch group (figure 3.4A, B, C).   There were no significant 
differences in pool size between animals in either diet strategy in any of the surfactant 
subfractions measured.  Furthermore, there was no significant difference in the 
percentage of cholesterol found within the surfactant between ventilation strategies or 
dietary conditions within each ventilation group (figure 3.4D).  
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Figure 3.3 Arterial oxygen (mmHg) throughout 120 minutes of low stretch (A) or high 
stretch (B) ventilation.  Values are means ± SE, n = 5-7/group 
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Figure 3.4 Surfactant pool sizes (mg PL/kg BW) between dietary conditions and 
ventilation strategies.   Measurement of (A) total surfactant (B) small aggregate (C) large 
aggregate pool sizes and (D) percentage of cholesterol LA.  Values are means ± SE, n = 
5-7/group 
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Figure 3.5 Concentration of protein (mg/kg BW) in surfactant among diet and ventilation 
groups. Values are means ± SE, n = 5-7/group. 
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Figure 3.5 shows the total protein within the lung lavage from rats in both diet conditions 
placed in each ventilation strategy.  Rats placed on low- or high-stretch MV had a 
significantly increased amount of total protein within their lavage as compared to non-
ventilated rats.  However, there were no significant differences in the amount of lavage 
protein between diet conditions.  
 
In additional experiment, a separate cohort of rats fed either high cholesterol or standard 
diet were exposed to high-stretch MV for 180 mins.  This was done to exacerbate the 
degree of injury as the PaO2 of rats placed on high-stretch ventilation after 120 mins did 
not significantly decrease over time. After 180 minutes of high-strech MV, there was a 
significant increase in the PIP of the animals from t=15-180 mins (figure 3.6A) as 
compared to BL and there was a significant decrease in the PaO2 of the animals after 150 
mins of ventilation (figure 3.6B).  However, there were no significant differences in 
terms of PIP or PaO2 between rats fed either diet at any time point during ventilation 
(figure 3.6A, B).   
 
Table 3.1 shows that after 180 minutes of high-stretch MV, there were no significant 
differences in phospholipid pool sizes for total surfactant, SA, LA or cholesterol levels in 
the lavage of rats fed either diet.  Also, it was revealed that there was no significant 
difference between rats fed a standard or high cholesterol diet in terms of the amount of 
total protein found within the lung lavage of rats placed on either diet after 180 minutes 
of high stretch mechanical ventilation. 
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Figure 3.6  Peak inspiratory pressure (cmH2O) (A) and arterial oxygenation content 
(mmHg) (B) throughout 180 minutes of high stretch mechanical ventilation.    Values are 
means ± SE, n = 4-5/group 
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Table 3.1 Surfactant pool sizes (mg PL/kg BW), lavage cholesterol levels (% of PL) and 
lavage protein levels (mg/kg BW) between dietary conditions after 180 minutes of high 
stretch mechanical ventilation.  Values are means ± SE, n = 4-5/group. 
 
 
 
 
 
 
 
 
Diet Total 
surfactant  
(mg PL/kg 
BW) 
SA 
(mg PL/kg 
BW) 
LA 
(mg PL/kg 
BW) 
Lavage 
cholesterol 
(% of PL) 
Lavage 
protein 
(mg/kg BW) 
Standard 6.37±0.92 2.03±0.35 
 
3.27±0.56 
 
10.45±1.26 
 
150.5±41.5 
 
High 
cholesterol 
6.24±0.87 
 
1.89±0.51 
 
2.06±0.15 
 
11.98±0.67 
 
196.6±77.8 
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3.3.2 Experiment #2: Acid-induced lung injury model 
Figure 3.7A shows the PIP of rats fed different diets after administration air or acid 
followed by 120 mins of MV.  Rats given a bolus of acid showed an increase in their PIP 
throughout the course of MV as compared to BL, however these increases were not 
significant.  There were no observed changes in the PIP of rats given a bolus of air at any 
time point during MV.   With regards to the effect of diet, rats fed either a standard or 
high cholesterol diet did not have any effect on PIP regardless of air or acid 
administration.  This effect was consistent throughout 120 mins of MV.   
 
Figure 3.7B shows the PaO2 of rats fed different diets after administration of air or acid 
during 120 mins of MV.  Although rats administered a bolus of acid resulted in 
significantly lower PaO2 as compared to rats administered air from t=15 mins onwards, 
rats fed either standard or high cholesterol diet did not show any significant differences 
regardless of air or acid administration any time point during ventilation.    
 
Analysis of collected lavage surfactant after air or acid administration and mechanical 
ventilation showed that there were no significant differences between the pool sizes of 
surfactant (Figure 3.8A), SA (Figure 3.8B) or LA (Figure 3.8C) in rats administered 
either air or acid and fed the standard or high cholesterol diet.  Similarly, there was no 
significant difference in the amount of cholesterol within the LA (Figure 3.8D) 
regardless of diet or air or acid administration. 
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With regards to the concentration of total protein (Figure 3.9) within the lavage after 120 
minutes of mechanical ventilation, there a significant increase in the amount of total 
protein and in the lavage of animals given acid as compared with air.  However, there 
were no significant differences in the amount of total protein in rats fed a standard or high 
cholesterol diet regardless of administration of air or acid. 
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Figure 3.7 Peak inspiratory pressure (cmH2O) (A) and arterial oxygenation content 
(mmHg) (B) in rats with and without acid induced lung injury and after 120 minutes of 
mechanical ventilation.    Values are means ± SE, n = 4-9/group. 
103 
 
Air Acid
0
2
4
6
8
10
12
Standard diet
High cholesterol diet
[P
h
o
s
p
h
o
li
p
id
]
(m
g
/k
g
 B
W
)
Air Acid
0
2
4
6
8
10
12
Standard diet
High cholesterol diet
[P
h
o
s
p
h
o
li
p
id
]
(m
g
/k
g
 B
W
)
Air Acid
0
2
4
6
8
10
12
Standard diet
High cholesterol diet
[P
h
o
s
p
h
o
li
p
id
]
(m
g
/k
g
 B
W
)
Air Acid
0
5
10
15
Standard diet
High cholesterol diet
C
h
o
le
s
te
ro
l
(%
 p
h
o
s
p
h
o
li
p
id
)
A B
DC
 
Figure 3.8 Surfactant pool sizes (mg PL/kg BW) between dietary conditions after 
acid/air treatment and 120 minutes of mechanical ventilation.   Measurement of (A) total 
surfactant (B) small aggregate (C) large aggregate pool sizes and (D) percentage of 
cholesterol within LA.  Values are means ± SE, n = 4-9/group. 
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Figure 3.9 Concentration of protein (mg/kg BW) in surfactant in rats fed a standard or 
high cholesterol diet with and without acid induced lung injury after 120 minutes of 
mechanical ventilation. *P<0.05 vs. rats fed a similar diet but treated with air.  Values are 
means ± SE, n = 4-9/group. 
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3.3.3 Experiment #3: Surfactant depletion model  
Rats from both diet groups were depleted of surfactant via repeated whole-lung saline 
lavages and ventilated for 120 mins.  There was no significant difference between the 
number of lavages necessary to deplete the rats of their surfactant between rats fed the 
standard diet or high cholesterol diet (5.12±0.35 vs. 4.88±0.40 lavages, p>0.05).  Table 
3.2 compares the surfactant, SA and LA phospholipid amounts in the first and final 
sequential lavages in rats fed the standard or high cholesterol diet.  There were no 
significant differences in the amount of surfactant, SA or LA found between each diet, 
but there was a significant decrease in the amount of phospholipid between the first and 
final sequential lavages across surfactant, SA and LA  (P<0.05) within each diet group. 
 
Figure 3.10A shows the PIP of rats at BL and after endogenous surfactant depletion fed 
either a standard or high cholesterol diet.  During the course of MV, there was a 
significant increase in the PIP as compared to BL, however there were no significant 
differences in the PIP of rats fed either a standard diet or high cholesterol diet.  This trend 
was evident throughout 120 mins of MV.   
 
Figure 3.10B shows the PaO2 of rats at BL and after exogenous surfactant depletion fed 
either a standard or high cholesterol diet.  Although there was a significant decrease in 
oxygenation after BL throughout the 120 mins of ventilation, there were no significant 
differences in terms of PaO2 of rats fed either a standard or high cholesterol diet at any 
time point during MV 
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Table 3.2 Surfactant phospholipids (PL) measured in the first and final sequential 
lavages of surfactant depleted rats.  *P<0.05 between first and final sequential lavages 
within each component of surfactant.  Values of surfactant, small aggregate (SA) and 
large aggregate (LA) phospholipids are shown as means  ±  SEM, n = 8/group.      
Diet Surfactant 
(mg PL/kg BW) 
SA 
(mg PL/kg BW) 
LA 
(mg PL/kg BW) 
First 
sequential 
lavage 
Final 
sequential 
lavage 
First 
sequential 
lavage 
Final 
sequential 
lavage 
First 
sequential 
lavage 
Final 
sequential 
lavage 
 
Standard 
 
1.94±0.25 
 
 
0.53±0.05* 
 
 
0.87±0.19 
 
 
0.20±0.04* 
 
 
1.01±0.09 
 
 
0.25±0.05* 
 
 
High 
cholesterol  
 
 
1.74±0.17 
 
 
0.67±0.08* 
 
 
0.78±0.13 
 
 
0.18±0.03* 
 
0.94±0.08 
 
 
0.39±0.05* 
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Figure 3.10 Peak inspiratory pressure (cmH2O) (A) and arterial oxygenation content 
(mmHg) (B) after endogenous surfactant depletion and 120 minutes of mechanical 
ventilation.    *P<0.05 vs. BL.  Values are means ± SE, n = 8/group. 
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Table 3.3 shows the analysis of phospholipid levels of surfactant subfractions, amount of 
cholesterol and protein in the lavage recovered after depletion and 120 minutes of 
mechanical ventilation.   There was no significant difference between rats fed a standard 
or high cholesterol diet in terms of the total surfactant, small aggregate or large aggregate 
phospholipid pool size.  Similarly, there was no significant difference in the amount of 
cholesterol found within the large aggregate component of surfactant and no significant 
differences were measured in the amount of protein in the lavage between the two diet 
groups.   
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Table 3.3 Surfactant pool sizes (mg PL/kg BW), lavage cholesterol levels (% of PL) and 
lavage protein levels (mg/kg BW) between dietary conditions after endogenous surfactant 
depletion and 120 mins of MV.  Values are means ± SE, n = 5/group. 
Diet Total 
surfactant PL 
(mg/kg BW) 
SA 
surfactant 
PL 
(mg/kg BW) 
LA 
surfactant 
PL 
(mg/kg BW) 
Lavage 
cholesterol 
(% of PL) 
Lavage 
protein 
(mg/kg BW) 
Standard 3.06±0.37 1.22±0.15 1.67±0.23 4.49±1.21 
 
37.7±6.6 
High 
cholesterol 
3.61±0.43 1.56±0.42 1.41±0.21 6.30±0.67 
 
56.4±16.3 
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3.4 Discussion 
 
Previous studies have implicated increased cholesterol within surfactant as a contributor 
to the material’s biophysical function (Chapter 2; Maruscak et al., 2008; Vockeroth et al., 
2010); however, it was unknown to what extent serum cholesterol levels would affect 
surfactant cholesterol.  It was hoped that by delineating this relationship, a potential 
patient population predisposed to ablated surfactant function could be identified as 
candidates for preventative therapies to reduce their risk of developing ARDS.  Our 
original hypothesis was that serum hypercholesterolemia would predispose the rats to 
developing more severe lung injury due to changes to their pulmonary surfactant system.  
Based on the data from our studies, serum hypercholesterolemia does not increase levels 
of surfactant cholesterol.  Despite having over a four-fold increase in serum cholesterol, 
none of the models used in this study had statistically significant differences between 
hypercholesterolemic and control rats with regards to the severity of lung injury, as 
measured through PIP, PaO2 or protein levels in their lavage regardless of the type of 
lung injury incurred.  Furthermore, surfactant composition was not significantly altered in 
rats fed either diet and analysis of surfactant cholesterol revealed nearly identical 
proportions of cholesterol between hypercholesterolemic and control rats.  Thus, it is 
concluded that diet-induced hypercholesterolemia does not lead to increased cholesterol 
content within pulmonary surfactant does not affect the development of lung injury. 
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We employed three distinct models of lung injury that allowed us to examine the role of 
serum hypercholesterolemia in different settings. Our first model was VILI in which high 
tidal volume ventilation cause lung injury. This model was utilized since it was 
previously shown to result in elevated levels of cholesterol in surfactant (Maruscak et al., 
2008).  Our second injury was induced by administration of acid to the lung; this is a 
clinically relevant model reflecting gastric acid aspiration in which a chemical burn 
initiates lung injury and is further propagated by recruitment of neutrophils into the 
alveolar space (Folkesson et al., 1995). Additionally, a previous study in our lab used an 
acid-aspiration model in the hypercholesteremic apolipoprotein-E null mice and 
demonstrated that these mice had more severe lung injury and higher pulmonary 
inflammation than wild-type mice (Yamashita et al., 2012).  Our third model was a 
surfactant depletion model in which the repetitive lavage procedure caused depletion of 
surfactant stores and allowed the evaluation of nascent surfactant produced and secreted 
during the two hour ventilation period (Lackmann et al., 1989). All three models 
demonstrated significant lung injury through physiological measurements and elevated 
proteins in the lavage.  By using these models in our study, we were able to investigate 
the effects of cholesterol across a broad range of injuries rather than focus on a specific 
sub-set. The fact that all three injury models demonstrated no significant effect of 
hypercholesteremia on the development of lung injury provides strong support for the 
conclusion that hypercholesteremia by itself is not a risk factor for the development of 
ARDS.            
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In addition to a lack of an effect of serum hypercholesterolemia on lung physiology, we 
also observed that the cholesterol diet did not affect the surfactant system compared to 
control rats in any of our models.  This finding was somewhat surprising in light of an 
earlier study conducted by McCrae and colleagues (2008) which examined surfactant’s 
biophysical activities from mice fed a high cholesterol diet.  These mice had a significant 
increase in both their serum cholesterol levels and the amount of cholesterol in their 
surfactant.  Furthermore, when the surfactant was tested, it was found that the surface 
active film had decreased ability to maintain patency at 37°C as compared to surfactant 
with endogenous levels of cholesterol (McCrae et al., 2008).  While our study did not test 
the biophysical properties of the surfactant collected, we did analyze the amount of 
cholesterol within surfactant and found that in all our experiments, in both injured and 
non-injured rats, there were no significant differences in the cholesterol levels of 
surfactant recovered from either hypercholesterolemic or control rats.  The difference in 
results between this study and the one conducted by McCrae and colleagues may be due 
to the different metabolic profiles between the different species used in the studies (rats 
vs. mice) or the length of diet used (14- 17 days vs. 16 weeks).  Because of the possible 
differences associated with species and/or acute vs. chronic exposure to 
hypercholesterolemia, future studies looking into the effects of chronic 
hypercholesterolemia in other species is warranted.   
 
The surfactant collected from our VILI rat model was the only injury model amongst the 
acid-induced lung injury and surfactant depleted rat models that showed an increase in 
cholesterol within surfactant.  The rats with VILI had ~12% (w/w PL) cholesterol within 
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their surfactant while our acid-injury model and surfactant depleted models had 
surfactant cholesterol levels of ~5-7% wt/wt PL.  This finding supports previous 
observations made by Maruscak and colleagues in 2008 when they found that surfactant 
from Sprague-dawley rats afflicted with VILI had increased surfactant cholesterol as 
compared to rats that did not have lung injury (Maruscak et al., 2008).  It is thought that 
mechanical stretch of lung epithelium stimulates alveolar type 2 cells to secrete surfactant 
(Wright et al., 1991; Edwards et al., 2001).  The composition of surfactant can also be 
affected by large tidal volumes used during ventilation (Veldhuizen et al., 1999).  For 
example, adult rabbits ventilated with higher tidal volumes had a higher ratio of SA/LA 
in their lavage as compared to rabbits ventilated with lower tidal volumes (Veldhuizen et 
al., 1999).  Thus the type of MV protocols used can affect surfactant’s composition and 
overall function.  It must be stated that MV alone does not seem to cause changes to 
surfactant’s composition or cholesterol content.  In our surfactant depleted model of 
injury, nascent surfactant collected from rats after 120 mins of non-injurious MV did not 
have an increased amount of surfactant cholesterol.  Based on this observation, we can 
conclude that mechanical over-distension of the lungs is responsible for increasing the 
amount of cholesterol within surfactant.  
 
Given the increase in the proportion of cholesterol within surfactant observed in our VILI 
model discussion regarding the contribution of high-stretch MV to this result is 
warranted.  Based on the data gathered, the elevation of cholesterol seen in this particular 
model is was not a consequence of increased lung permeability.  This is supported by our 
observation that there was no significant increase in total protein levels in the lungs of 
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animals fed either the standard or high cholesterol diet in our VILI model.  Furthermore, 
animals with lung injury in our other models showed an increase in the amount of protein 
in their lavage compared to non-injured animals; however, lavage samples from these 
animals did not contain elevated cholesterol regardless of diet.  These observations 
indicate that in our VILI model, the increase in cholesterol was not due to cholesterol 
leaking into the lungs directly from circulation implying that high-stretch ventilation 
changes the lung’s surfactant metabolism.   
 
Although we were successful in the development of hypercholesterolemic rats due to diet 
the onset of their hypercholesterolemia was acute and does not represent the normal 
development of the condition which requires chronic ingestion of high-fat and high-
cholesterol foods (Steinberg, 2005).  To address this, future studies can extend the 
duration of a hypercholesterolemic diet to better mimic a chronic exposure to high levels 
of systemic cholesterol.  However, the risk of developing other cardiovascular factors, 
such as hypertension and atherosclerosis (Steinberg, 2005), could have impacted our 
results.  Delineating the specific contribution of serum hypercholesterolemia on the 
cardiovascular and surfactant systems would have shifted the focus away from our 
original hypothesis that dealt with only the effects of hypercholesterolemia the 
development of lung injury due to surfactant.  Furthermore, we believe that increasing the 
duration of the diet would not have led to increases in surfactant cholesterol levels.  The 
synthesis of new surfactant requires 7 – 10 hours and the half-life of phosphatidylcholine, 
which accounts for 80% of surfactant phospholipids, is approximately 17 hours (Jacbos et 
al., 1982).  Given that our rats fed a high cholesterol diet had a significantly higher 
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amount of serum cholesterol levels after 14-17 days on the diet, a sufficient period of 
time had passed wherein newly metabolized surfactant could have incorporated excess 
cholesterol from the serum.  
 
3.5 Conclusions 
 
In conclusion, diet-induced serum hypercholesterolemia did not predispose rats to the 
development of more severe ARDS or affect their surfactant composition.  However, 
increases in surfactant cholesterol levels can occur by over-distension of alveoli and this 
increase is not present in other models of lung injury.  Our data argues against either 
hypercholesteremia or direct leak of cholesterol from the serum as a mechanism by which 
cholesterol levels within surfactant are affected, other mechanism require further 
examination.   
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Chapter 4  
4 Future directions and overall significance 
 
4.1 Introduction 
 
This thesis focused on two aspects of the role of elevated cholesterol in surfactant 
function and ARDS.  In chapter 2, we established that elevated cholesterol in human 
surfactant affects the material’s biophysical properties in vitro.  We also showed evidence 
that surfactant with high cholesterol is detrimental to the oxygenation of ventilated and 
surfactant depleted rats.  Importantly, this study also showed that SP-A can mitigate the 
inhibition caused by elevated cholesterol improving both the biophysical properties of 
surfactant with high cholesterol and improving the oxygenation of rats treated with 
surfactant containing high cholesterol.  Given the evidence that high cholesterol affects 
surfactant function, chapter 3’s main objective was to determine to whether serum 
hypercholesterolemia predisposed rats to the development of more severe lung injury and 
changes to surfactant composition.  We fed rats a high cholesterol diet which elevated 
their serum cholesterol levels to four-times greater than in our control rats.  However, our 
data indicate that regardless of the form of lung injury incurred, there was no difference 
in the degree of lung injury sustained between diet and control rats and that within each 
mode of injury there were no changes to the composition of surfactant regardless of the 
type of diet.   
 
122 
 
Based on the results from these two chapters, we can conclude that high cholesterol in 
surfactant affects the material’s biophysical properties and oxygenation, but SP-A can 
mitigate these effects.  Furthermore, although cholesterol is an inhibitor to surfactant 
function, cholesterol levels within surfactant are not affected by diet alone. The purpose 
of this final chapter is to examine preliminary data determining whether cholesterol-
mediated surfactant inhibition affects ventilated human trauma patients and to discuss 
future experiments.  Finally, this chapter will conclude by discussing the overall clinical 
significance of our findings thus far. 
 
4.2 The role of MV in cholesterol-mediated surfactant 
dysfunction 
 
Mechanical ventilation (MV) is a supportive therapy necessary in patients that are 
otherwise unable to maintain proper oxygenation (Lee & Slutsky, 2001); however, 
studies suggest that the use of MV can also propagate the development of lung injury 
(Webb & Tierney, 1974; Dreyfuss & Saumon, 1998; Brower et al., 2000; Veldhuizen et 
al., 2001).  Moreover, the contribution of cholesterol in lung injury developed due to MV 
(i.e. ventilator induced lung injury, “VILI”) has shown that there are increases in the 
amounts of cholesterol within surfactant (Maruscak et al., 2008; Vockeroth et al., 2010).  
This is further supported by our observations made in chapter 3 which showed that, 
regardless of diet, rats with VILI had increased cholesterol in their surfactant when 
compared to rats with other forms of lung injury such as acid aspiration or surfactant 
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depletion.  Despite these findings, limitations with these animal models of VILI create a 
dissonance between observations in a laboratory setting and clinical realities.  
 
Animal studies of VILI, including ours presently, have predominantly focused on the use 
of high-tidal volume MV for brief periods of time in animals (Maruscak et al., 2008; 
Vockeroth et al., 2010).  In contrast, critically ill patients require the use of MV for 
prolonged periods of time extending to days.  Furthermore, VILI studies utilize high-
stretch MV to develop lung injury within a short time frame.  However, clinical MV 
strategies predicate the use of low-tidal volume strategies which have reduced the 
mortality rate of patients with ARDS from 40 to 30% according to the large, multi-center 
trial conducted by ARDSnet (Brower et al., 2000).  Given the discrepancy between 
laboratory models of VILI and clinical realities, it is unknown whether the consequences 
of MV can be applied to a ventilated, human patient population.  
 
4.2.1 The role of cholesterol in ventilated, human trauma patients. 
In order to investigate the role of cholesterol in patients undergoing MV, nine surfactant 
samples were obtained from eight human trauma patients.  These patients were placed on 
different ventilation strategies as determined by their attending physician, represented a 
range of ages from 20 – 84 and had different causes of trauma.  Common amongst all 
patients was the requirement for the use of MV for a minimum of 24 hours.  We tested 
the patient’s surfactant biophysical properties on the CBS with and without incubation 
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with methyl-beta cyclodextrinn (MBCD) – a water-soluble molecule capable of 
sequestering cholesterol from lipid films such as surfactant.   
 
4.2.2 Preliminary results 
 
4.2.2.1 Adsorption 
The surfactant large aggregates collected from the trauma patients were tested on the 
CBS for the material’s adsorption properties.  Methods as outlined in chapter 2 were used 
for this experiment.  Figure 4.1 shows the surface tension of human trauma patient 
surfactant after 300 s of adsorption with and without incubation with MBCD. Overall, 
surfactant samples collected from the human trauma patients showed significantly 
reduced surface tension after sample incubation with cholesterol sequestering agent, 
MBCD after 300 s of adsorption.  Other time points during the 300 s of adsorption were 
measured and at all other points, a similar effect was observed with surfactant samples 
having significantly lower surface tension after incubation with MBCD than without.   
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Figure 4.1 Surface tension of human trauma patient surfactant after 300 s of initial 
adsorption with and without treatment of MBCD.  Closed squares represent patient LA 
without incubation with cholesterol sequestering agent MBCD while closed triangles 
represent patient LA incubated with MBCD.  Lines connecting squares and triangles 
represent LA from the same patient. Values are reported as mean ± standard error; 
*P<0.05, n = 8. 
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4.2.2.2 Minimum achievable surface tension 
Figure 4.2, A, B, C and D shows the minimum achievable surface tension of the 
surfactant obtained from eight human trauma patients before incubation with MBCD 
through dynamic expansion-compression cycles #1, 2, 5 and 10.  Overall, surfactant 
samples tested in the presence of MBCD showed a significant reduction in minimum 
achievable as compared to surfactant not incubated with MBCD.  This observation was 
consistent through cycles 1, 2, 5 and 10 of the dynamic expansion-compression cycles.   
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Figure 4.2 Minimum achievable surface tension of human trauma patient surfactant after 
cycle 1 (A), cycle 2 (B), cycle 5 (C) and cycle 10 (D) of dynamic compression-expansion 
with and without the addition of MBCD.  Closed squares represent patient LA without 
incubation with cholesterol sequestering agent MBCD while closed triangles represent 
patient LA incubated with MBCD.  Lines connecting squares and triangles represent LA 
from the same patient. Values are reported as mean ± standard error *P<0.05, n = 8. 
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4.2.3 Discussion  
 
Based on this preliminary data presented, it is concluded that cholesterol mediated-
surfactant inhibition occurs in ventilated human patients.  This is further evidence that 
MV can affect the functional properties of surfactant in part due to affecting cholesterol 
levels in the material.  In contrast with previous studies utilizing animal models of VILI, 
this preliminary study focused on a non-homogenous population of human patients with 
non-specific forms of trauma requiring the use of prolonged MV.  Therefore, our findings 
indicate that human patients placed on prolonged MV have surfactant with dysfunctional 
biophysical properties which can be improved by the sequestration of cholesterol.  Future 
studies investigating the mechanisms of ventilation affecting surfactant cholesterol 
metabolism is warranted. 
 
4.3 Reconstitution of SP-A into ventilated human 
patient surfactant 
 
In chapter 2, we determined that the addition of SP-A to surfactant with high levels of 
cholesterol improves the material’s biophysical capabilities which results in improved 
oxygenation in ventilated, surfactant depleted rats.  This observation emphasizes the 
importance of SP-A in mitigating surfactant dysfunction including inhibition due to 
elevated cholesterol.  Although our preliminary experiment determined that surfactant 
obtained from ventilated human patients are inhibited by cholesterol, the surfactant 
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samples underwent organic-solvent extraction prior to testing on the CBS and lacks SP-
A.  Therefore, it is currently unknown whether the addition of SP-A to human patient 
surfactant would improve the material’s biophysical function.  
 
To investigate this, surfactant samples from ventilated human trauma patients can be 
reconstituted with 5% SP-A in a similar fashion as in the surfactant samples employed in 
chapter 2.  After, the biophysical function of the human trauma patient surfactant with 
SP-A can be determined on the CBS as we have described presently in this chapter and 
previously in chapter 2. Given SP-A’s ability to mitigate the inhibitory effects of serum 
proteins, cholesterol and decreased PL concentrations in surfactant (Cockshutt et al., 
1990; Korfhagen et al., 1996; Yu & Possmayer, 1998; Yu et al., 1999; Keating et al., 
2007), it is expected that the addition to SP-A to human trauma patient surfactant will 
result in improved surface tension reducing capabilities.  This information would be 
invaluable to the development of effective exogenous surfactant therapies to treat severe 
lung disorders such as ARDS.  
 
To date, the application of exogenous surfactant therapy has only proven effective when 
treating neonatal respiratory distress syndrome (Yee & Scarpelli, 1991; Jobe, 1993) and 
not ARDS (Lewis & Veldhuizen, 2002; Maruscak & Lewis, 2006).    The difficulty in 
treating ARDS is impaired surfactant function due to serum-protein inhibition, altered PL 
profiles within the material and, cholesterol inhibition (Veldhuizen et al., 1995; Gunther 
et al., 1996; Panda et al., 2004) which can also inhibit exogenously applied surfactant.  
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However, if we can provide evidence that SP-A can mitigate surfactant inhibition in 
humans, then perhaps exogenous surfactant therapies reconstituted with SP-A may prove 
to be an effective pharmacological treatment for severe lung maladies such as ARDS.  
 
Limitations in the developmental process of exogenous surfactant preparations make this 
proposition difficult.  Clinically used surfactants undergo a process of organic-solvent 
extraction which removes inhibitory peptides and also to concentrate the material.  
However, this process also removes SP-A.  Furthermore, reconstitution of SP-A is not 
currently feasible since the artificial production of human SP-A yields very small 
quantities and is prohibitively expensive.  Nevertheless, the ability of SP-A to prevent 
various forms of surfactant inhibition is an important consideration into its importance in 
exogenous surfactant therapies.  Surfactants with SP-A may represent an effective 
pharmacological treatment for patients with lung disorders which may reduce rates of 
mortality. 
 
4.4 The effect of chronic serum hypercholesterolemia 
on surfactant function and lung injury 
 
Data in chapter 3 indicated that high of serum cholesterol levels do not affect surfactant 
composition or the development of lung injury. This is in contrast to findings by McCrae 
and colleagues (2008) who showed that mice with hypercholesterolemia had elevated 
surfactant cholesterol levels and their surfactant had increased patency when analyzed in 
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vitro.  With that said, species differences (mice vs. rats) and the duration of high 
cholesterol diet (16 weeks vs. 14-17 days) are apparent between the two studies.  
Furthermore, the acute development of hypercholesterolemia present in our models of 
lung injury in chapter 3 do not reflect the development of hypercholesterolemia in 
humans.  Typically, dyslipidemia in humans occurs over a prolonged period of time and 
chronic ingestion of high fat and high cholesterol food.  If it is revealed that surfactant is 
affected by chronic hypercholesterolemia, this result may signify a specific patient 
population at risk for the development of lung injuries such as ARDS.    Therefore, 
investigation into the effects of a prolonged high cholesterol diet on surfactant 
composition and function may be warranted. 
 
To test whether chronic exposure to a high cholesterol diet does change surfactant 
cholesterol levels, a study can be conducted in which rats are fed the diet used in chapter 
3 for 16 weeks as done by McCrae and colleagues (2008).  Following, these rats can be 
randomized into the three models of lung injury as outlined in chapter 3: VILI, acid-
induced and surfactant depleted.  The results from these experiments can be used to 
determine whether chronic hypercholesterolemia affects the development of lung injury 
and would more closely resemble the chronic nature of hypercholesterolemia as present 
in a human patient population.  Furthermore, the biophysical properties of the material 
can be examined on the CBS as previously described.  
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This experiment would help to determine whether chronic exposure to high cholesterol 
levels affects surfactant composition and function.  However, due to the chronic nature of 
this study, however, the potential development of cardiovascular maladies may pose a 
limitation.  Specifically, the development of atherosclerotic plaques due to the high 
cholesterol diet may cause systemic inflammation which may cause lung inflammation 
and ultimately lung injury.  Thus, the lung injury would not be due to cholesterol directly, 
but rather due to the development of cardiovascular abnormalities.  Secondly, the rate of 
turnover for surfactant is approximately 7-10 hours (Jacbos et al., 1982).  This indicates 
that in our 14-17 day diet used in chapter 3, we would have expected changes to 
surfactant’s composition to have occurred as a result of the high cholesterol diet.  
Therefore, it is unclear whether extending the high cholesterol diet to a period of weeks 
would have any effect on surfactant as well.   
 
4.5 Analyzing the topography of surfactant films with 
elevated cholesterol and SP-A 
 
The biophysical data obtained in chapter 2 showed that SP-A can mitigate surfactant 
dysfunction caused by high levels of cholesterol.  While the CBS enabled us to accurately 
measure the surface tension reducing capabilities of our surfactant film samples, it does 
not provide insight into the molecular mechanisms of cholesterol mediated impairment 
and how SP-A is able to mitigate this.  Two ways to determine the effects of SP-A on 
surfactant films with high cholesterol on a molecular level is to use atomic force 
microscopy (AFM) and time-of-flight-secondary ion mass spectrometry (ToF-SIMS).  
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AFM can be used to measure height-differences in a given surfactant film and provide 
information about the topographic organization of lipids in the film.  ToF-SIMS is a 
mass-spectrometry technique which allows identification of specific components of 
surfactant within specific regions of the film.   
 
Studies utilizing AFM imaging and ToF-SIMS on surfactant containing cholesterol has 
been previously conducted (Panda et al., 2004; Leonenko et al., 2006, Leonenko et al., 
2006; 2007; Keating et al., 2007).  Using AFM, Panda and colleagues (2004) showed that 
surfactant from injured lungs lacked organized domains which are thought to be crucial 
for proper surfactant function.  Furthermore, a recent study showed that BLES 
reconstituted with cholesterol had smaller and more numerous micro-domain as 
determined by ToF-SIMS (Keating et al., 2007).    
 
Based on these observations, cholesterol affects surfactant function by modifying the 
lipid organization of surfactant.  Since we have shown that SP-A is able to mitigate the 
biophysical impairments caused by high cholesterol, it would be interesting to examine if 
SP-A is able to facilitate this by affecting the topographical organization of these lipid 
films.  To do this, we can utilize surfactant samples reconstituted with SP-A and 
cholesterol to levels similar to those used in the CBS in chapter 2 and then analyze these 
samples using AFM and ToF-SIMS. The use of AFM and ToF-SIMS may elucidate the 
mechanisms which enable SP-A to mitigate cholesterol-mediated surfactant dysfunction.   
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4.6 Overall relevance 
 
The results from this thesis emphasize the importance of cholesterol as a mechanism of 
surfactant dysfunction, especially within the context of MV, and the role of SP-A in 
mitigating this form of surfactant dysfunction.  Given the evidence which shows that 
surfactant inhibition occurs in patients with severe lung disorders such as ARDS, it is 
important to continue investigating the mechanisms behind surfactant dysfunction to 
better understand the pathophysiology of the disease.  Furthermore, although serum 
hypercholesterolemia did not predispose the development of more severe lung injury or 
changes to surfactant composition in our models, further research into determining 
whether specific patient populations are at greater risk of developing lung injuries should 
be pursued.  It is hoped that by identifying a patient population with greater risk of 
developing lung injuries, therapeutic options, such as exogenous surfactant therapy, can 
be administered prior to the development of lung injury.  This tactic may prove effective 
in protecting patients from the development of pulmonary maladies such as ARDS and 
decrease the syndrome’s overall rate of mortality.   
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